Sirona Dental Systems (SIRO) 10-K 22 Nov 13 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Sep. 30, 2013	Nov. 18, 2013	Mar. 31, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Document period end date	30-Sep-13	'	'
Amendment flag	'false	'	'
Current fiscal year end date	'--09-30	'	'
Entity central index key	'0001014507	'	'
Entity current reporting status	'Yes	'	'
Entity filer category	'Large Accelerated Filer	'	'
Entity registrant name	'SIRONA DENTAL SYSTEMS, INC.	'	'
Entity voluntary filers	'No	'	'
Entity well known seasoned issuer	'Yes	'	'
Entity common stock shares outstanding	'	55,005,670	'
Entity public float	'	'	$3,435,842,773
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEET

CONSOLIDATED BALANCE SHEET (USD $)	Sep. 30, 2013	Sep. 30, 2012
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$241,745	$151,088
Restricted cash	681	0
Accounts receivable, net of allowance for doubtful accounts of $1,588 and $1,408, respectively	145,212	132,569
Inventories, net	109,175	81,007
Deferred tax assets	31,370	24,781
Prepaid expenses and other current assets	32,556	17,622
Income tax receivable	2,345	2,213
Total current assets	563,084	409,280
Property, plant and equipment, net of accumulated depreciation and amortization of $156,730 and $125,706, respectively	182,737	143,351
Goodwill	672,086	631,077
Intangible Assets, net of accumulated amortization of $503,130 and $446,447, respectively	301,718	288,556
Other non-current assets	5,620	9,382
Deferred tax assets	13,174	12,888
Total assets	1,738,419	1,494,534
LIABILITIES AND SHAREHOLDERS' EQUITY	'	'
Trade accounts payable	73,235	51,961
Short-term debt and current portion of long-term debt	447	478
Income taxes payable	9,319	14,906
Deferred tax liabilities	745	817
Accrued liabilities and deferred income	162,341	118,075
Total current liabilities	246,087	186,237
Long-term debt	75,000	75,000
Deferred tax liabilities	131,455	122,441
Other non-current liabilities	27,447	16,852
Pension related provisions	65,985	61,629
Deferred income	34,401	40,000
Total liabilities	580,375	502,159
Shareholders' equity	'	'
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued and outstanding)	0	0
Common stock ($0.01 par value; 95,000,000 shares authorized; 57,213,615 shares issued and 54,999,436 shares outstanding at Sept. 30, 2013; 56,598,045 shares issued and 55,051,673 shares outstanding at Sept. 30, 2012)	572	566
Additional paid-in capital	723,288	699,279
Treasury stock (at cost) 2,214,179 shares held at cost at Sept. 30, 2013; 1,546,372 shares held at cost at Sept. 30, 2012	-111,955	-69,058
Excess of purchase price over predecessor basis	-49,103	-49,103
Retained earnings	584,216	437,471
Accumulated other comprehensive income/(loss)	8,607	-29,797
Total Sirona Dental Systems, Inc. shareholders' equity	1,155,625	989,358
Noncontrolling interests	2,419	3,017
Total shareholders' equity	1,158,044	992,375
Total liabilities and shareholders' equity	$1,738,419	$1,494,534

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Sep. 30, 2013	Sep. 30, 2012
In Thousands, except Share data, unless otherwise specified
CONSOLIDATED BALANCE SHEETS	'	'
Allowance for doubtful accounts	$1,588	$1,408
Accumulated depreciation and amortization	156,730	125,706
Accumulated amortization	$503,130	$446,447
Preferred stock par value per share	$0.01	$0.01
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value per share	$0.01	$0.01
Common stock shares authorized	95,000,000	95,000,000
Common stock shares issued	57,213,615	56,598,045
Common stock shares outstanding	54,999,436	55,051,673
Treasury stock shares	2,214,179	1,546,372

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
CONSOLIDATED INCOME STATEMENTS	'	'	'	'	'	'	'	'	'	'	'
Revenue	$278,604	$283,157	$267,326	$272,404	$247,364	$242,007	$231,864	$258,116	$1,101,491	$979,351	$913,866
Cost of sales	135,313	131,670	122,620	120,533	115,285	113,567	107,215	119,333	510,136	455,400	430,214
Gross profit	143,291	151,487	144,706	151,871	132,079	128,440	124,649	138,783	591,355	523,951	483,652
Selling, general and administrative expense	83,372	79,702	83,992	85,783	76,912	72,434	72,667	73,646	332,849	295,659	277,081
Research and development	14,649	15,729	15,102	14,095	12,606	13,092	13,638	13,286	59,575	52,622	55,530
Provision for doubtful accounts and notes receivable	-152	148	547	70	-338	-504	728	39	613	-75	96
Net other operating income	-2,500	-2,500	-2,500	-6,914	-2,500	-2,500	-2,500	-2,500	-14,414	-10,000	-10,000
Operating income	47,922	58,408	47,565	58,837	45,399	45,918	40,116	54,312	212,732	185,745	160,945
(Gain)/loss on foreign currency transactions, net	1,848	4,510	1,417	4,580	-382	2,675	1,350	2,230	12,355	5,873	-5,668
(Gain)/loss on derivative instruments	-738	-901	2,564	-1,346	-2,147	2,686	-2,936	436	-421	-1,961	3,302
Interest expense, net	822	788	830	970	984	866	1,014	903	3,410	3,767	3,883
Other (income)/expense	-1,227	362	342	340	-529	-218	228	262	-183	-257	-101
Income before taxes	47,217	53,649	42,412	54,293	47,473	39,909	40,460	50,481	197,571	178,323	159,529
Income tax provision	10,741	12,876	10,179	15,226	12,622	9,180	9,305	11,611	49,022	42,718	35,744
Net income	36,476	40,773	32,233	39,067	34,851	30,729	31,155	38,870	148,549	135,605	123,785
Less: Net income attributable to noncontrolling interests	241	223	575	765	115	431	634	593	1,804	1,773	1,992
Net income attributable to Sirona Dental Systems, Inc.	$36,235	$40,550	$31,658	$38,302	$34,736	$30,298	$30,521	$38,277	$146,745	$133,832	$121,793
Income per share (attributable to Sirona Dental Systems, Inc. common shareholders)	'	'	'	'	'	'	'	'	'	'	'
Basic	$0.66	$0.74	$0.58	$0.70	$0.63	$0.55	$0.55	$0.69	$2.67	$2.41	$2.19
Diluted	$0.65	$0.72	$0.56	$0.68	$0.62	$0.53	$0.54	$0.67	$2.61	$2.36	$2.13
Weighted average shares - basic	54,980,287	55,002,236	54,928,332	55,004,471	55,128,904	55,507,312	55,683,043	55,783,648	54,979,044	55,524,188	55,735,422
Weighted average shares - diluted	56,090,777	56,220,901	56,202,296	56,327,927	56,388,273	56,717,943	56,916,390	57,121,505	56,213,992	56,755,396	57,292,996

CONSOLIDATED_STATEMENT_OF_COMP

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)	'	'	'
Net income	$148,549	$135,605	$123,785
Other comprehensive income/(loss), net of tax:	'	'	'
Cumulative translation adjustment	36,715	-49,995	-6,041
Net gain/(loss) on derivative financial instruments (hedging)	582	-1,258	0
Unrecognized elements of pension cost, net of tax	942	10,176	-2,434
Total other comprehensive income/(loss)	38,239	-41,077	-8,475
Total Comprehensive Income (Loss)	186,788	94,528	115,310
Less: Comprehensive income/(loss) attributable to noncontrolling interests	1,639	1,802	1,909
Comprehensive income/(loss) attributable to Sirona Dental Systems, Inc. shareholders	$185,149	$92,726	$113,401

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)	Total	Common share capital	Additional paid-in capital	Treasury Stock	Excess of purchase price over predecessor basis	Retained earnings	Accumulated other comprehensive income	Total Sirona Dental Systems, Inc. Sjareholders	Noncontrolling Interests
In Thousands, except Share data
Balance at Sep. 30, 2010	$807,633	$553	$652,698	($284)	($49,103)	$181,846	$19,701	$805,411	$2,222
Balance, shares at Sep. 30, 2010	'	55,305,581	'	'	'	'	'	'	'
Issuance of common stock upon exercise of options	11,148	10	11,138	'	'	'	'	11,148	'
Issuance of common stock upon exercise of options, shares	950,628	959,116	'	'	'	'	'	'	'
Purchase of treasury stock (at cost)	-19,465	'	'	-19,465	'	'	'	-19,465	'
Purchase of treasury stock (at cost), shares	'	-449,374	'	'	'	'	'	'	'
Stock compensation	7,604	'	7,604	'	'	'	'	7,604	'
Tax benefit of stock options exercised and net effect of vesting of RSUs/PSUs	7,552	'	7,552	'	'	'	'	7,552	'
One-time non-cash compensation charge (payment by shareholder - Note 24)	6,625	'	6,625	'	'	'	'	6,625	'
Dividend distribution to noncontrolling interest	-487	'	'	'	'	'	'	'	-487
Comprehensive Income	115,310	'	'	'	'	121,793	-8,392	113,401	1,909
Balance at Sep. 30, 2011	935,920	563	685,617	-19,749	-49,103	303,639	11,309	932,276	3,644
Balance, shares at Sep. 30, 2011	'	55,815,323	'	'	'	'	'	'	'
Issuance of common stock upon exercise of options	3,935	3	3,932	'	'	'	'	3,935	'
Issuance of common stock upon exercise of options, shares	254,860	305,625	'	'	'	'	'	'	'
Purchase of treasury stock (at cost)	-49,309	'	'	-49,309	'	'	'	-49,309	'
Purchase of treasury stock (at cost), shares	'	-1,069,275	'	'	'	'	'	'	'
Stock compensation	8,623	'	8,623	'	'	'	'	8,623	'
Tax benefit of stock options exercised and net effect of vesting of RSUs/PSUs	367	'	367	'	'	'	'	367	'
Purchase of shares from noncontrolling interest	'	'	740	'	'	'	'	'	-740
One-time non-cash compensation charge (payment by shareholder - Note 24)	0	'	'	'	'	'	'	'	'
Dividend distribution to noncontrolling interest	-1,689	'	'	'	'	'	'	'	-1,689
Comprehensive Income	94,528	'	'	'	'	133,832	-41,106	92,726	1,802
Balance at Sep. 30, 2012	992,375	566	699,279	-69,058	-49,103	437,471	-29,797	989,358	3,017
Balance, shares at Sep. 30, 2012	55,051,673	55,051,673	'	'	'	'	'	'	'
Issuance of common stock upon exercise of options	7,932	6	7,926	'	'	'	'	7,932	'
Issuance of common stock upon exercise of options, shares	512,221	615,570	'	'	'	'	'	'	'
Purchase of treasury stock (at cost)	-42,897	'	'	-42,897	'	'	'	-42,897	'
Purchase of treasury stock (at cost), shares	'	-667,807	'	'	'	'	'	'	'
Stock compensation	12,813	'	12,813	'	'	'	'	12,813	'
Tax benefit of stock options exercised and net effect of vesting of RSUs/PSUs	3,854	'	3,854	'	'	'	'	3,854	'
Purchase of shares from noncontrolling interest	-1,386	'	-584	'	'	'	'	-584	-802
One-time non-cash compensation charge (payment by shareholder - Note 24)	0	'	'	'	'	'	'	'	'
Dividend distribution to noncontrolling interest	-1,435	'	'	'	'	'	'	'	-1,435
Comprehensive Income	186,788	'	'	'	'	146,745	38,404	185,149	1,639
Balance at Sep. 30, 2013	$1,158,044	$572	$723,288	($111,955)	($49,103)	$584,216	$8,607	$1,155,625	$2,419
Balance, shares at Sep. 30, 2013	54,999,436	54,999,436	'	'	'	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities	'	'	'
Net income	$148,549	$135,605	$123,785
Adjustments to reconcile net income to net cash provided by operating activities	'	'	'
Depreciation and amortization	75,596	77,749	81,173
Compensation Charge Paid By Shareholders	0	0	6,625
(Gain)/loss on disposal of property, plant and equipment	93	-91	0
(Gain)/loss on derivative instruments	-421	-1,961	3,302
(Gain)/loss on foreign currency transactions, net	12,355	5,873	-5,668
Deferred income taxes	-2,665	-17,274	-17,173
Amortization of debt issuance cost	554	631	587
Share-based compensation expense	12,813	8,623	7,604
Changes in assets and liabilities	'	'	'
Accounts receivable	-13,174	-38,301	-14,202
Inventories	-26,778	8,824	-19,542
Prepaid expenses and other current assets	-14,345	-1,935	8,861
Restricted cash	-698	646	20
Other non current assets	-278	-290	-453
Trade accounts payable	16,398	4,600	6,191
Accrued liabilities and deferred income	22,857	-6,674	2,566
Other non-current liabilities	7,555	15,144	-2,997
Income taxes receivable	-59	1,954	-697
Income taxes payable	-6,327	8,246	-1,129
Net cash provided by operating activities	232,025	201,369	178,853
Cash flows from investing activities	'	'	'
Investment in property, plant and equipment	-70,715	-47,131	-56,958
Proceeds from sale of property, plant and equipment	83	105	0
Prepayments for other assets	0	-4,612	0
Purchase of intangible assets	-1,194	-514	-203
Purchase of long-term investments	0	0	-145
Acquisition of businesses, net of cash acquired	-35,019	0	-20,836
Net cash used in investing activities	-106,845	-52,152	-78,142
Cash flows from financing activities	'	'	'
Repayments of short-term and long-term debt	-98	-434,364	0
Proceeds from borrowings	0	138,932	0
Purchase of treasury stock	-42,897	-49,309	-19,465
Debt issuance cost	0	-2,765	0
Purchase of shares from noncontrolling interest	-1,386	0	0
Dividend distributions to noncontrolling interest	-1,435	-1,689	-487
Common shares issued under share based compensation plans	7,926	3,932	11,138
Tax effect of common shares exercised under share based compensation plans	-183	-181	8,501
Net cash used in financing activities	-38,073	-345,444	-313
Change in cash and cash equivalents	87,107	-196,227	100,398
Effect of exchange rate change on cash and cash equivalents	3,550	1,456	-6,306
Cash and cash equivalents at beginning of period	151,088	345,859	251,767
Cash and cash equivalents at end of period	241,745	151,088	345,859
Supplemental information	'	'	'
Interest paid	2,848	2,966	3,380
Interest capitalized	184	237	450
Income taxes paid	65,663	44,795	46,923
Acquisition of businesses	'	'	'
Current assets	5,185	0	201
Non-current assets	61,237	0	47,255
Current liabilities	-7,835	0	-269
Non-current liabilities	-11,951	0	-16,139
Fair value of total consideration transferred	46,636	0	31,048
Settlement of balances	-4,544	0	0
Cash paid	-36,673	0	-20,895
Fair value of liabilities incurred	$5,419	$0	$10,153

The_Company_and_its_operations

The Company and its operations	12 Months Ended
	Sep. 30, 2013
Company and its Operations [Abstract]	'
The Company and its Operations	'
	1. The Company and its Operations
	Sirona Dental Systems, Inc. (“Sirona,” the “Company,” “we,” “us,” and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries) is the leading global manufacturer of high-quality, technologically advanced dental equipment, and is focused on developing, manufacturing and marketing innovative systems and solutions for dentists around the world. We offer a broad range of products across all major segments of the dental technology market including CEREC and our other CAD/CAM systems, digital intra oral and 2D and 3D panoramic imaging systems, treatment centers, and instruments. The Company acquired Schick Technologies, Inc. (“Schick”) in 2006, in a transaction accounted for as a reverse acquisition (the “Exchange”), further expanding our global presence and product offerings and strengthening our research and development capabilities. Sirona has served equipment dealers and dentists worldwide for more than 130 years. The Company's headquarters are located in Long Island City, New York, with its primary facility located in Bensheim, Germany, as well as other support, manufacturing, assembling, and sales and service facilities located around the globe.

Basis_of_presentation_and_summ

Basis of presentation and summary of significant accounting policies	12 Months Ended
	Sep. 30, 2013
Basis Of Presentation And Summary Of Significant Accounting Policies [Abstract]	'
Basis of Presentation and Summary of Significant Accounting Policies	'
	2. Basis of Presentation and Summary of Significant Accounting Policies
	The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (''U.S. GAAP''). All amounts are reported in thousands of U.S. Dollars ($), except per share amounts or as otherwise disclosed.
	Fiscal Year
	The Company's fiscal year is October 1 to September 30.
	Principles of Consolidation
	The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries.
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from estimates. Some of the more significant estimates include allowances for doubtful accounts, inventory valuation reserves, purchase accounting assumptions, depreciable lives of assets, amortization periods, impairment of long-lived assets, deferred tax asset valuation allowance, discounts to customers, pension reserves, provisions and warranty reserves.
	Foreign Currency
	The functional currency for foreign operations has been determined in all cases to be the local currency. Adjustments resulting from translating foreign functional-currency assets and liabilities are recorded in shareholders' equity as a component of accumulated other comprehensive income. Gains or losses resulting from transactions in other than the functional currency are reflected in the consolidated statements of income, except for intra-group transactions of a long-term nature, which are recorded in shareholders' equity as a component of accumulated other comprehensive income.
	Comprehensive Income
	In addition to net income, comprehensive income includes other charges or credits to equity other than those resulting from transactions with shareholders. Accumulated other comprehensive income relates to foreign currency translation adjustments related to the Company's foreign subsidiaries, changes in the fair value of cash flow hedges, as well as to the pension adjustment resulting from the application of ASC 715-30, Compensation-Retirement Benefits – Defined Benefit Plans-Pension.
	On October 1, 2012, the Company adopted the new accounting guidance for reporting comprehensive income (“CI”) (ASU 2011-05, Presentation of Comprehensive Income). This new guidance requires that all non-owner changes in shareholders' equity be presented either (1) in a single continuous statement of comprehensive income or (2) in two separate but consecutive statements. As a result, the Company reported all such changes in two separate, consecutive statements: Condensed Consolidated Statements of Income and Condensed Consolidated Statement of Comprehensive Income (“CI Statement”). The Company previously reported these items in its Consolidated Statement of Changes in Equity (“Equity Statement”). As a result of adoption, this detailed information was moved from the Equity Statement to the new and separate CI Statement. The details for these items (category and type of change, current period movements, and related tax effects) are reported separately in Note 5 to the consolidated financial statements. All related disclosures have been adjusted accordingly. Prior year amounts and presentation associated with non-owner changes in shareholders' equity have been adjusted accordingly to conform to the adoption.
	Revenue Recognition
	The Company's main revenue stream results from the delivery of dental equipment. The Company also enters into revenue arrangements that consist of multiple deliverables of its product and service offerings. Additionally, certain products, primarily in our CAD/CAM and Imaging segments, may contain embedded software that functions together with the product to deliver the product's essential functionality.
	Revenue, net of related discounts and allowances, is recognized when products or equipment have been shipped, when persuasive evidence of the arrangement exists, the price is fixed or determinable, collectability is reasonably assured, title and risk of loss has passed to customers based on the shipping terms, no significant obligations remain, and allowances for discounts, returns, and customer incentives can be reliably estimated. The Company offers discounts to its distributors if certain conditions are met. Discounts and allowances are primarily based on the volume of products purchased or targeted to be purchased by the individual customer or distributor. Discounts are deducted from revenue at the time of sale or when the discount is offered, whichever is later. The Company estimates volume discounts based on the individual customer's historical and estimated future product purchases. Returns of products, excluding warranty related returns, are infrequent and insignificant. Amounts received from customers in advance of product shipment are classified as deferred income until the revenue can be recognized in accordance with the Company's revenue recognition policy.
	Services: Service revenue is generally recognized ratably over the contract term as the specified services are performed. Amounts received from customers in advance of rendering of services are classified as deferred income until the revenue can be recognized upon rendering of those services.
	Extended Warranties: The Company offers its customers an option to purchase extended warranties on certain products. The Company recognizes revenue on these extended warranty contracts ratably over the life of the contract. The costs associated with these extended warranty contracts are recognized when incurred.
	Multiple-Element Arrangements (“MEAs”): Arrangements with customers may include multiple deliverables, including any combination of equipment, services, and extended warranties. The deliverables included in the Company's MEAs are separated into more than one unit of accounting when (i) the delivered equipment has value to the customer on a stand-alone basis, and (ii) delivery of the undelivered service element(s) is probable and substantially in the control of the Company. Arrangement consideration is then allocated to each unit, delivered or undelivered, based on the relative selling price (“RSP”) of each unit of accounting based first on vendor-specific objective evidence (“VSOE”) if it exists and then based on estimated selling price (“ESP”).
	VSOE – In most instances, products are sold separately in stand-alone arrangements. Services are also sold separately through renewals of contracts with varying periods. The Company determines VSOE based on its pricing and discounting practices for the specific product or service when sold separately, considering geographical, customer, and other economic or marketing variables, as well as renewal rates or stand-alone prices for the service element(s).
	ESP – The estimated selling price represents the price at which the Company would sell a product or service if it were sold on a stand-alone basis. When VSOE does not exist for all elements, the Company determines ESP for the arrangement element based on sales, cost and margin analysis, as well as other inputs based on its pricing practices. Adjustments for other market and Company-specific factors are made as deemed necessary in determining ESP.
	After separating the elements into their specific units of accounting, total arrangement consideration is allocated to each unit of accounting according to the nature of the revenue as described above and application of the RSP method. Total recognized revenue is limited to the amount not contingent upon future transactions.
	Research and Development
	Amounts spent by the Company for research and development (R&D) efforts are recorded as R&D expenses when incurred. R&D costs relate primarily to internal costs for salaries, direct overhead costs and outside vendors. The Company capitalizes costs of equipment used for general R&D if it has alternative future use. The depreciation related to this capitalized equipment is included in the Company's R&D costs. Software development costs incurred prior to the attainment of technological feasibility are considered R&D and are expensed as incurred.
	Warranty Expense
	The Company offers warranties on its products for periods between one and three years. Estimated future warranty obligations related to product sales are charged to operations in the period in which the related revenue is recognized. These estimates are based on historical warranty experience and other relevant information of which the Company is aware. Estimated warranty expenses are recorded as an accrued liability and selling, general and administrative expense.
	Shipping and Handling Costs
	Shipping and handling costs charged to customers are included in revenues, and the associated expense is recorded in cost of sales for all periods presented.
	Advertising Costs
	Advertising costs are expensed as incurred and recorded within selling, general and administrative expense. During the last three fiscal years, advertising expense was as follows:
			Advertising Costs
			$'000s
	Fiscal year ended September 30, 2013	$	39,285
	Fiscal year ended September 30, 2012		34,228
	Fiscal year ended September 30, 2011		33,091
	Pension Benefits
	The Company has defined benefit and defined contribution pension plans and an early retirement plan. Sirona recognizes changes in the funded status of its benefit plans, not yet recognized in the income statement, in other comprehensive income until they are amortized as a component of net periodic benefit cost in accordance with the provisions of ASC 715-30, Compensation-Retirement Benefits – Defined Benefit Plans-Pension.
	Pension expense is recognized on an accrual basis over the employee's approximate service periods. Defined benefit pension costs are determined by using an actuarial method, which provides for the deferral of actuarial gains and losses (in excess of a specified corridor) that result from changes in assumptions or actual experience differing from that assumed. Costs relating to changes in the benefit plan as well as the transition obligation are amortized. Disclosure of the components of periodic pension cost is also required. When purchase accounting is applied, pension liabilities are recognized for the projected benefit obligation in excess of plan assets.
	For the defined contribution pension plans, the net pension cost is equal to the contributions required by the plan.
	The Company also has an early retirement plan, Altersteilzeit (''ATZ''), which allows certain German employees who have been accepted into the plan to retire at 60 rather than at the legal retirement age of 67. Eligible employees are those who have attained the age of 59, have completed 12 years of service, and have been accepted to participate in the ATZ plan. Accepted employees join for a period of 2-4 years, during which they work in full active service for 50% of the agreed ATZ plan period, the remaining 50% of the plan period being the passive phase during which the employee does not work.  Alternatively, the employee may work for 50% of the time for the entire agreed ATZ plan period. The alternative actually executed is decided via mutual agreement between Sirona and the employee. During the active service period, the employees receive 50% of their salary plus a bonus payment equal to 35% of their salary, and the remaining 50% of their salary, plus a bonus payment equal to 35% of their salary, is paid during the inactive service period. The Company recognizes the salary component of the ATZ plan over the period from the beginning of the ATZ period to the end of the active service period.
	Income Taxes
	Differences between the basis of assets and liabilities for financial statement purposes and for tax return purposes are recorded as deferred tax assets or deferred tax liabilities in the accompanying consolidated financial statements. Deferred taxes represent the tax consequences in future years of these differences at each balance sheet date, based on the enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. The provision (benefit) for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities. A valuation allowance is established when it is more likely than not that the deferred tax assets are not realizable. The effect on deferred tax assets and liabilities of a change in the tax rates is recognized in income as an adjustment to income tax expense in the period that includes the enactment date. See Note 10, “Income Taxes” for additional information.
	Cash and Cash Equivalents
	All highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Investments in money market funds are carried at fair value. All other cash equivalents are stated at cost, which approximates fair value.
	Restricted Cash
	Restricted cash represents cash balances that are i) pledged as collateral to financial institutions that provide security for prepayments from customers and other bonds or ii) held as security deposits for leased office space.
	Accounts Receivable
	Accounts receivable are stated at the invoiced amount, less allowances for doubtful accounts, which approximates fair value given their short-term due dates. Collectability of accounts receivable is regularly reviewed and is based upon managements' knowledge of customers and compliance with credit terms. The allowance for doubtful accounts is adjusted based on such evaluation, with the corresponding expense included in the provision for doubtful accounts and notes receivable in the Consolidated Statements of Income. Accounts receivable balances are written off when management deems the balances uncollectible.
	Inventory
	Inventory is carried at the lower of cost or market value. Cost is determined using standard costing, which approximates the weighted average cost method. In addition to direct material and direct labor costs, certain costs related to the overhead and production expenses are included in inventory. Inventory reserves are provided for risks relating to slow moving, unmarketable, and obsolete items.
	Business Acquisitions
	The Company acquires businesses as well as partial interests in businesses. Acquired businesses are accounted for using the acquisition method of accounting, which requires that all assets and liabilities are recorded at their respective fair values. Any excess of the purchase price over estimated fair values of net assets is recorded as goodwill. The assumptions made in determining fair value assigned to acquired assets and liabilities as well as asset lives can materially impact the results of operations.
	The Company obtains information during due diligence and through other sources to arrive at respective fair values. Examples of factors and information that the Company uses to determine the fair values include: tangible and intangible asset evaluations and appraisals; evaluations of existing contingencies and liabilities; product line integration information; and information systems compatibilities. If the initial accounting for an acquisition is incomplete by the end of the quarter in which the acquisition occurred, the Company will record a provisional estimate in the financial statements. The provisional estimate will be finalized as soon as information becomes available but no later than one year from the acquisition date.
	Investments in Companies
	Investments in associated companies over which the Company can exercise significant influence but not effective control are accounted for using the equity method. Investments in associated companies over which the Company cannot exercise significant influence or effective control are accounted for at cost.
	Property, Plant and Equipment
	Property, plant, and equipment are recorded at historical cost plus the fair value of asset retirement costs, if any and if reasonably estimable, less accumulated depreciation. Additions, improvements and major renewals, which extend the useful life of the asset, are capitalized; maintenance and repairs are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in current operating income. Development costs for external use software incurred after the establishment of technological feasibility are capitalized and amortized to cost of revenues on a straight-line basis over the expected useful life of the software. Costs of software developed for internal use incurred during the development of the application are capitalized and amortized to operating expense on a straight-line basis over the expected useful life of the software. Prepayments for property, plant, and equipment are classified as property, plant, and equipment and are not depreciated until the assets are received and placed into service.
	The cost of plant and equipment is depreciated using the straight-line method over the following estimated useful lives of the respective assets:
			Minimum Useful Life (years)	Maximum Useful Life (years)
		Buildings	25	50
		Building improvements and leasehold improvements	5	10
		Machinery and technical equipment	3	10
		Software and software licenses	3	5
Finite-Lived Intangible Assets
Finite-lived intangible assets are amortized according to the pattern in which the economic benefit of the asset is used up over their estimated useful lives, as shown below:
		Minimum Useful Life (years)	Maximum Useful Life (years)
	Patents and licenses	10	13
	Technologies and Dealer Relationships	1	15
Impairment of Long-Lived and Finite-Lived Assets
Long lived assets held for use by the Company are reviewed for impairment whenever events or circumstances provide evidence that suggests the carrying amount of the asset may not be recoverable. The Company performs ongoing impairment analysis on technology-related intangible assets. Determination of whether an impairment exists is based upon a comparison of the identifiable undiscounted cash flows of the assets or groups of assets to the carrying amount of the assets or groups of assets. If impaired, the resulting charge reflects the excess of the asset's carrying amount over its fair value.
Goodwill and Indefinite-Lived Intangible Assets
Goodwill and indefinite lived intangible assets, consisting of certain trademarks and in-process research and development (IPR&D), are not amortized, but are reviewed for potential impairment on an annual basis as of September 30, or whenever events or circumstances indicate that the carrying amount may not be recoverable. First, a qualitative assessment is performed on reporting units to determine if further quantitative impairment testing is necessary. If this qualitative assessment indicates that a possible impairment exists, a quantitative impairment test is performed. Goodwill impairment tests are based upon a comparison of the fair value of the reporting units to their respective carrying amount. If the carrying amount of the reporting unit exceeds its fair value, the goodwill impairment loss is measured as the excess of the carrying amount of goodwill over its implied fair value. If impairment is identified on indefinite-lived intangibles, the resulting charge reflects the excess of the asset's carrying amount over its fair value.
Other non-current assets
Other non-current assets and prepaid expenses include capitalized debt issuance costs. The costs are amortized using the effective interest method. The non-current unamortized balance of such debt issuance costs was $1,156 and $1,681 as of September 30, 2013 and 2012, respectively.
Derivative Financial Instruments
The Company enters into forward foreign currency contracts in order to manage currency risks arising from its forecasted and firmly committed foreign currency denominated cash flows. The Company enters into these contracts to limit the foreign exchange rate risk for periods generally not to exceed six months. The Company also enters into interest rate swaps to manage its interest rates on its long term debt.
The Company does not utilize financial instruments for speculative purposes. The Company accounts for derivative financial instruments in accordance with ASC 815, Derivatives and Hedging. This Topic prescribes requirements for designation and documentation of hedging relationships and ongoing assessments of effectiveness in order to qualify for hedge accounting. The Company has designated its interest rate swaps as qualifying hedge instruments and therefore applies hedge accounting. The Company has not designated any of its foreign currency derivatives as qualifying for hedge accounting under ASC 815. All derivative instruments are recognized as either assets or liabilities in the consolidated balance sheet at fair value. The fair value of the forward foreign currency contracts and interest rate swaps are included within prepaid and other current assets or current accrued liabilities, depending on whether they are an asset or a liability. The change in fair value is recognized within ''Gains (losses) on derivative instruments'' in the consolidated statement of income for the forward foreign currency contracts and the ineffective portion of the interest rate swaps. The effective portion of interest rate swaps is recognized within “Accumulated other comprehensive income/(loss)” in the consolidated balance sheet.
Fair Value of Financial Instruments
Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, bank loans, foreign currency forward contracts, interest rate swaps, and certain liabilities related to fixed and intangible asset purchases and liabilities for business acquisitions primarily from earn-out features. The carrying values of cash, cash equivalents, accounts receivable, and accounts payable approximate their respective fair values because of the short-term nature of these items. The fair value of the foreign currency forward contracts and interest rate swaps are estimated based on information such as quotes from financial institutions. The fair values of the acquisition-related liabilities are based on discounted valuations of commercial assumptions made by Company management of stipulations governed in the underlying purchase agreements.

Business_Acquisitions

Business Acquisitions	12 Months Ended
	Sep. 30, 2013
Business Acquisitions [Abstract]	'
Business Acquisitions	'
	3. Business Acquisitions
	On October 8, 2012, the Company acquired 100% of the outstanding shares of capital stock of a technology company that develops and manufactures dental products. The results of its operations have been included in the consolidated financial statements since this date. The results were not material to the consolidated financial statements.
	The fair value of total consideration transferred for this acquisition totaled $46.6 million, consisting of cash of $36.7 million, settlements of prior balances, and contingent consideration arrangements. The contingent consideration arrangements require the Company to pay the former owners additional amounts contingent upon revenue milestones. These contingent arrangements provide for payments ranging from $0 up to a total of approximately $13.0 million over the expected life cycle of the company's major product. The fair value of the contingent arrangements at acquisition date was $5.4 million and are being remeasured through settlement (amounts included in Note 22), with changes in fair value recorded in income. The fair value of the contingent arrangements as of September 30, 2013, was $5.9 million, with the change in fair value of $0.3 million recorded in other (income)/expense in the income statement for the fiscal year 2013.
	On May 16, 2011, we acquired 100% of the outstanding shares of capital stock of a development stage technology company. The results of its operations have been included in the consolidated financial statements since this date. The results were not material to the consolidated financial statements. The fair value of total consideration transferred for this acquisition totaled $31.0 million, consisting of cash of $20.9 million and contingent consideration arrangements. The contingent consideration arrangements provide for payments ranging from $0 up to a total of $28 million (undiscounted) and vary over a period of up to 6 years, ending in fiscal 2018. As of September 30, 2011, we recorded initial goodwill of $4.9 million and contingent consideration arrangements of $10.2 million related to this acquisition. The fair value of the contingent arrangements as of September 30, 2013 and 2012, was $7.5 million and $7.9 million, respectively (amounts included in Note 22), with the current-period change in fair value of $(0.4) million recorded in other (income)/expense in the income statement for the fiscal year 2013.

Employee_ShareBased_Compensati

Employee Share-Based Compensation	12 Months Ended
	Sep. 30, 2013
Employee Share-Based Compensation [Abstract]	'
Employee Share-Based Compensation	'
	4. Employee Share-Based Compensation
	ASC 718, Compensation – Stock Compensation, requires that all share based compensation arrangements, including grants of stock option awards to employees, be recognized based on the estimated fair value of the share-based payment award.
	Schick Legacy Plans
	Share-based awards outstanding under Schick's legacy stock option plans continue to be outstanding. At the date of the acquisition of Schick, 862,220 vested and 458,179 unvested options were outstanding. Options granted under these plans have 10 year contractual lives and vesting periods of between 2 to 4 years from the grant date.
	In contemplation of the acquisition by Sirona, Schick conditionally granted employees and consultants 1,530,000 options upon the acquisition by Sirona. The four year vesting period of that grant commenced with the closing of the business acquisition on June 20, 2006.
	All Schick legacy plans have expired, and accordingly, no further options may be granted under such plans.
	Equity Incentive Plan
	Stock options, restricted stock shares, restricted stock units (“RSU”), and performance-based stock units (“PSU”) have been issued to employees, directors, and consultants under the Company's 2006 Equity Incentive Plan (“2006 Plan”). The 2006 Plan provides for granting in total up to 4,550,000 stock options, incentive stock, restricted stock, RSU's, and PSU's. The 2006 Plan received stockholder approval at the Company's Annual Meeting of Stockholders held on February 27, 2007, and was amended on February 25, 2009. To cover the exercise of options and vesting of RSU's and PSU's, the Company generally issues new shares from its authorized but unissued share pool. As of September 30, 2013, 675,830 shares were available for future grant under the 2006 Plan.
	Restricted and Performance-Based Stock Units
	In fiscal year 2013, the Company granted 180,036 RSU's with an average value of $63.19, the value of which representing the average of the closing prices at grant dates.
	RSU's and PSU's generally vest in annual tranches over a period of three to four years. The PSU's were granted to three executive officers of the Company and vest three years from the date of the grant provided the Company achieves earnings targets specified in the grant. All grants expire ten years after the date of the grant. RSU's and PSU'S do not have voting rights or rights to dividends prior to vesting. The value of each RSU and PSU grant is determined by the closing price at the date of grant. Share-based compensation expense for the entire award is recognized straight-line over the service period of the last separately vesting tranche of the award.
	Stock Options
	In fiscal year 2013, the Company granted 154,500 stock options with a weighted average exercise price of $63.45 and weighted average fair value of $21.74 at the grant date. Grants generally vest over four years. All grants expire ten years after the date of the grant.
	The fair value of options granted under the 2006 Plan were estimated using the Black-Scholes option pricing model using assumptions in the following table. The exercise price is equal to the fair market value of Sirona's stock at the grant date. Expected volatility is based on the Company's history stock price volatility. The risk-free rate is based on the U.S. Treasury yield curve in effect at the day of grant and has a term equal to the expected life of the option. The expected life represents the period of time the options are expected to be outstanding based on anticipated grantee behavior. The expected dividend yield is based on the Company's history of not paying regular dividends in the past and the Company's current intention not to pay dividends in the foreseeable future.
			Year ended		Year ended
			30-Sep-13		30-Sep-12
	Expected Volatility		38.23%		39.17%
	Risk-free rate		0.70%		0.91%
	Expected term		5 years		5 years
	Expected dividends		-		-
	Compensation Costs
	The following tables summarize compensation expense charged to income for stock-based compensation and additional information for the fiscal years ended September 30, 2013, 2012, and 2011, respectively:
			Year ended		Year ended		Year ended
			30-Sep-13		30-Sep-12		30-Sep-11
			$'000s
	Compensation Expense
	Cost of sales	$	138	$	113	$	136
	Selling, general and administrative (1)		12,537		8,383		7,297
	Research and development		138		127		171
		$	12,813	$	8,623	$	7,604
	(1) For the fiscal year 2013, this includes the compensation charge from the first quarter of $3,764 for the modification of share based awards in connection with the Transition Agreement for the former CEO and Chairman.
			Year ended		Year ended		Year ended
			30-Sep-13		30-Sep-12		30-Sep-11
			$'000s (except where noted)
	Additional Information
	Tax Information
	Income tax benefit recognized for share-based compensation	$	-3,731	$	-2,486	$	-1,948
	Tax benefit realized from share-based compensation	$	-9,799	$	-3,282	$	-11,483
	Future Costs
	Total compensation cost to be recognized in future periods related to outstanding non-vested share-based compensation awards	$	19,599	$	17,718	$	14,818
	Weighted-average period expected for recognition of cost (in years)		2.6		2.6		2.6
	Restricted and Performance-Based Stock Unit Activity
	The following is a summary of Sirona's RSU and PSU activity for the fiscal years ended September 30, 2013 and 2012:
			Year ended September 30, 2013
			Restricted Stock Units				Performance-based Stock Units
			Number of shares		Weighted average market price at grant		Number of shares		Weighted average market price at grant
	Outstanding at beginning of period		585,187	$	38.47		13,000	$	36.78
	Granted		180,036		63.19		-		0
	Vested		-157,039		37.37		-		0
	Forfeited		-37,256		41.49		-		0
	Outstanding at end of period		570,928		46.37		13,000		36.78
			Year ended September 30, 2012
			Restricted Stock Units				Performance-based Stock Units
			Number of shares		Weighted average market price at grant		Number of shares		Weighted average market price at grant
	Outstanding at beginning of period		462,265	$	36.99		13,000	$	36.78
	Granted		216,400		41.15		-		0
	Vested		-75,478		36.26		-		0
	Forfeited		-18,000		41.98		-		0
	Outstanding at end of period		585,187		38.47		13,000		36.78
	Stock Option Activity
	The following is a summary of Sirona's stock option activity for the fiscal years ended September 30, 2013, 2012, and 2011:
			Year ended
			30-Sep-13
				Weighted average
		Number of options		exercise price
Outstanding at beginning of period		2,157,113	$	17.63
Granted		154,500		63.45
Exercised		-512,221		15.49
Forfeited		-21,290		42.17
Outstanding at end of period		1,778,102		21.93
thereof vested and exercisable		1,469,883
		$'000s
Intrinsic value of options exercised	$	27,339
Total fair value of options vested	$	2,033
Aggregate intrinsic value of exercisable stock options	$	75,245
Weighted average remaining contractual life (in years)		3.3
		Year ended
		30-Sep-12
				Weighted average
		Number of options		exercise price
Outstanding at beginning of period		2,207,312	$	15.05
Granted		227,375		40.41
Exercised		-254,860		15.44
Forfeited		-22,714		19.12
Outstanding at end of period		2,157,113		17.63
		$'000s
Intrinsic value of options exercised	$	8,789
Total fair value of options vested	$	1,738
Aggregate intrinsic value of exercisable stock options	$	67,617
Weighted average remaining contractual life (in years)		4.2
		Year ended
		30-Sep-11
				Weighted average
		Number of options		exercise price
Outstanding at beginning of period		3,173,403	$	14.04
Exercised		-950,628		11.72
Expired		-2,636		19.86
Forfeited		-12,827		11.83
Outstanding at end of period		2,207,312		15.05
		$'000s
Intrinsic value of options exercised	$	35,789
Total fair value of options vested	$	2,016
Aggregate intrinsic value of exercisable stock options	$	39,326
Weighted average remaining contractual life (in years)		4.9

Comprehensive_Income

Comprehensive Income	12 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Comprehensive Income	'
	5. Accumulated Other Comprehensive Income/(Loss)
	The components of accumulated other comprehensive income for the last three fiscal years are summarized below. Cumulative translation adjustments are generally not adjusted for income taxes since they relate to indefinite investments in foreign subsidiaries.
			September 30,
			2013
			Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain/(loss) from hedging instruments		Total
			$'000s
	Balance at beginning of period	$	-34,017	$	5,478	$	-1,258	$	-29,797
	Current increase / (decrease)		36,715		1,387		970		39,072
	Income tax (expense) / benefit		-		-445		-388		-833
	Balance at end of period		2,698		6,420		-676		8,442
	Less: Other comprehensive income/(loss) attributable to noncontrolling interests, net of tax		-165				-		-165
	Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	2,863	$	6,420	$	-676	$	8,607
			September 30,
			2012
			Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain/(loss) from hedging instruments		Total
			$'000s
	Balance at beginning of period	$	16,007	$	-4,698	$	-	$	11,309
	Current increase / (decrease)		-49,995		14,046		-2,096		-38,045
	Income tax (expense) / benefit		-		-3,870		838		-3,032
	Balance at end of period		-33,988		5,478		-1,258		-29,768
	Less: Other comprehensive income/(loss) attributable to noncontrolling interests, net of tax		29				-		29
	Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	-34,017	$	5,478	$	-1,258	$	-29,797
			September 30,
			2011
			Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain/(loss) from hedging instruments		Total
			$'000s
	Balance at beginning of period	$	21,965	$	-2,264	$	-	$	19,701
	Current increase / (decrease)		-6,041		-3,360		-		-9,401
	Income tax (expense) / benefit				926		-		926
	Balance at end of period		15,924	$	-4,698		-		11,226
	Less: Other comprehensive income/(loss) attributable to noncontrolling interests, net of tax		-83						-83
	Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	16,007	$	-4,698	$	-	$	11,309

Accounts_receivable

Accounts receivable	12 Months Ended
	Sep. 30, 2013
Accounts Receivable [Abstract]	'
Account receivable	'
	6. Accounts Receivable
	The allowance for doubtful accounts developed as follows:
					Additions
			Balance at Beginning of Period		Charged to Cost and Expenses		Charged to Other Accounts		Deductions		Balance at End of Period
			$'000s
	For the year ended September 30, 2013	$	1,408	$	748	$	-	$	568	$	1,588
	For the year ended September 30, 2012		1,868		834		-		1,294		1,408
	For the year ended September 30, 2011		1,681		1,034		-		847		1,868

Inventories_net

Inventories, net	12 Months Ended
	Sep. 30, 2013
Inventories Net [Abstract]	'
Inventories, net	'
	7. Inventories, Net
				September 30,		September 30,
				2013		2012
				$'000s
		Finished goods	$	72,621	$	50,878
		Work in progress		14,377		12,349
		Raw materials		37,501		29,561
				124,499		92,788
		Inventory reserve		-15,324		-11,781
			$	109,175	$	81,007

Property_plant_and_equipment_n

Property, plant and equipment, net	12 Months Ended
	Sep. 30, 2013
Property, Plant And Equipment, Net [Abstract]	'
Property, plant and equipment, net	'
	8. Property, Plant and Equipment, Net
						Accumulated
						Depreciation
				Gross		and Amortization		Net
				$'000s
		As of September 30, 2013
		Land	$	12,643	$	-	$	12,643
		Buildings, building improvements and
		leasehold improvements		40,785		13,379		27,406
		Machinery and technical equipment		186,015		110,956		75,059
		Software and software licenses		70,564		32,395		38,169
		Prepayments for property, plant and equipment		29,460		-		29,460
			$	339,467	$	156,730	$	182,737
						Accumulated
						Depreciation
				Gross		and Amortization		Net
				$'000s
		As of September 30, 2012
		Land	$	12,103	$	-	$	12,103
		Buildings, building improvements and
		leasehold improvements		38,442		10,800		27,642
		Machinery and technical equipment		155,838		94,439		61,399
		Software and software licenses		54,942		20,467		34,475
		Prepayments for property, plant and equipment		7,732		-		7,732
			$	269,057	$	125,706	$	143,351
	Depreciation and amortization expense for the fiscal years ended September 30, 2013, 2012, and 2011 was $ 34,993, $ 29,800, and $ 26,232.
	Amortization expense includes amortization of capitalized software development costs for the fiscal years ended September 30, 2013, 2012, and 2011 of $8,834, $6,376, and $5,360.
	Buildings and leasehold improvements includes office space that is leased under operating leases to third parties with a historical cost of $1,237 and $1,385 and a carrying amount of $400 and $497 at September 30, 2013 and 2012, respectively.
	Prepayments for property, plant, and equipment for the fiscal year ended September 30, 2013 include payments totaling $16.9 million made for building construction, machinery, and special tools in connection with the expansion of instruments manufacturing capacity.

Intangible_assets_and_goodwill

Intangible assets and goodwill	12 Months Ended
	Sep. 30, 2013
Intangible Assets And Goodwill [Abstract]	'
Intangible assets and goodwill	'
	9. Intangible Assets and Goodwill
	On June 30, 2005, Sirona Holdings Luxco S.C.A. (''Luxco''), a Luxembourg-based holding entity owned by funds managed by Madison Dearborn Partners, Beecken Petty O'Keefe, management and employees of Sirona, obtained control over the Sirona business. The transaction was effected by using new legal entities, Sirona Holding GmbH and its wholly owned subsidiary Sirona Dental Services GmbH, to acquire 100% of the interest in Sirona Dental Systems Beteiligungs- und Verwaltungs GmbH, the former parent of the Sirona business through a leveraged buy-out transaction (the ''MDP Transaction''). The MDP Transaction was accounted for as a leveraged buyout transaction, in a manner similar to a business combination. Certain members of Sirona management who were deemed to be in the control group held equity interests in Sirona Group prior to and subsequent to the MDP Transaction (''Continuing Shareholders''). The interests of the Continuing Shareholders have been reflected at the predecessor basis, resulting in 9.15% of each asset and liability acquired being valued at historical cost at June 30, 2005. The remaining 90.85% interest in each asset and liability was recognized at fair value at June 30, 2005 and the excess of purchase price over predecessor basis is presented as a separate component of shareholders' equity. Intangible assets and goodwill were primarily recorded in the MDP Transaction and the reverse acquisition of Schick on June 30, 2006.
	Amortization expense for finite-lived identifiable intangible assets for the fiscal years ended September 30, 2013, 2012, and 2011, and the annual estimated amortization expense related to these intangible assets for the next five fiscal years are as follows:
			Amortization Expense for Finite-Lived Assets
			$'000s
	Fiscal year ended September 30, 2013		40,603
	Fiscal year ended September 30, 2012		47,949
	Fiscal year ended September 30, 2011		54,941
	Year ending September 30,		Annual Estimated Amortization Expense (Future)
			$'000s
	2014		34,212
	2015		28,183
	2016		21,435
	2017		12,465
	2018		8,657
	The following table presents details of intangible assets, related accumulated amortization and goodwill:
					Accumulated
			Gross		amortization		Net
			$'000s
	As of September 30, 2013
	Patents & Licenses	$	152,238	$	99,112	$	53,126
	Trademarks		130,760		864		129,896
	Technologies and dealer relationships		491,313		403,154		88,159
	In-process research & development		30,537		-		30,537
			804,848		503,130		301,718
	Goodwill		672,086		-		672,086
	Total intangible assets	$	1,476,934	$	503,130	$	973,804
					Accumulated
			Gross		amortization		Net
			$'000s
	As of September 30, 2012
	Patents & Licenses	$	134,251	$	83,241	$	51,010
	Trademarks		126,245		728		125,517
	Technologies and dealer relationships		434,166		362,478		71,688
	In-process research & development		40,341		-		40,341
			735,003		446,447		288,556
	Goodwill		631,077		-		631,077
	Total intangible assets	$	1,366,080	$	446,447	$	919,633
	The change in the value of goodwill from September 30, 2012 to September 30, 2013 is mainly attributable to (i) foreign currency fluctuations, with an impact of $ 22,969, (ii) the acquisition of a technology company in the first quarter of fiscal year 2013, which resulted in $ 18,167 of goodwill, and (iii) a reduction in goodwill by $ (127) as a result of tax benefits received subsequent to the exchange for options that were vested and included in the determination of purchase price at the time of that acquisition.
	Aside from normal amortization for the current fiscal year, the change in the value of intangible assets, excluding goodwill and the acquired IPR&D, from September 30, 2012 to September 30, 2013, is mainly attributable to (i) acquired patents and developed technology in connection with the acquisition of a technology company in the first quarter of fiscal year 2013, with an impact of $11,113 and $3,079, respectively, and (ii) foreign currency fluctuations, with an impact of $ 8,721.
	The change in IPR&D during the period resulted from (i) the acquisition of a technology company in the first quarter of fiscal year 2013 and (ii) the realization and commercialization of the single project that was in process at September 30, 2012 with a carrying value of $40.3 million, which was reclassified as a technology asset during the current period. The total carrying value of IPR&D of $30.5 million as of fiscal year end 2013 represented a single project. The remaining estimated cost to complete the project was $3.5 million. The project is 55% through the development phase; the remaining steps prior to product release are further development, prototype finalization and testing, integration and field testing, and regulatory approvals. The percentage of completion for the full project is 40%, and we anticipate project completion in the second half of 2015.

Income_Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2013
Income Taxes [Abstract]	'
Income taxes	'
	10. Income Taxes
	The income tax provision is comprised of the following:
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
		Current
		Domestic (U.S.)	$	-9,050	$	-8,628	$	-14,638
		Foreign		-55,493		-46,570		-39,473
		Total Current		-64,543		-55,198		-54,111
		Deferred
		Domestic (U.S.)		4,765		4,452		8,571
		Foreign		10,756		8,028		9,796
		Total Deferred		15,521		12,480		18,367
		Total	$	-49,022	$	-42,718	$	-35,744
	The significant components of our net asset (liability) representing deferred income tax balances are as follows:
				September 30,		September 30,
				2013		2012
				$'000s
		Employee share-based compensation	$	16,764	$	16,288
		Receivables		2,443		3,011
		Inventory reserve		1,527		1,339
		Property, plant and equipment		-13,718		-11,264
		Intangible assets and goodwill		-122,079		-115,405
		Debt issuance costs		-1,628		-2,044
		Employee benefit accruals		7,997		7,072
		Deferred income		2,234		-353
		Valuation allowances		-3,249		-876
		IC profit elimination		8,638		6,736
		Other		2,603		1,521
		Tax loss carryforward		10,812		8,386
		Net deferred income tax asset (liability)	$	-87,656	$	-85,589
	In assessing the recoverability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon sufficient taxable income within the carry-back years and the generation of future taxable income during the periods in which those temporary differences and tax loss carry-forwards become deductible. Management considers taxable income in the carry-back years, if carry back is permitted in the tax law, the projected future taxable income (including the realization of future taxable temporary differences), and tax planning strategies in making this assessment.
	As of September 30, 2013, the Company had $35,082 of gross tax loss carry-forwards subject to expiration as follows:
		Year of expiration		Losses
				$'000s
		2014	$	111
		2015		1,048
		2016		388
		2017		1,379
		2018		1,557
		2019 - 2034		15,105
		Subtotal		19,588
		Indefinite		15,494
		Total	$	35,082
	The Company recognized a valuation allowance of $ 3,249 at September 30, 2013, ($ 876 at September 30, 2012) on deferred tax assets of $10,812 ($8,386 at September 30, 2012) predominantly relating to tax loss carry-forwards, as management believes that it is more likely than not that the benefits of those existing tax loss carry-forwards will not be realized within the period those tax losses are deductible.
	The difference between the U.S. federal income tax rate and the Company's income tax provision included in the consolidated statements of income consisted of the following:
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
	Income before income taxes		$	197,571	$	178,323	$	159,529
	Reconciliation of provision for income taxes:
	Computed tax provision			-69,782		-66,559		-55,801
	Foreign tax differential			26,524		25,821		23,863
	Nondeductible expenses			-236		-1,298		-1,826
	Permanent differences relating
	to German trade taxes			-1,421		-1,220		-1,143
	Subpart F income net of tax credit			-		-		-113
	Share-based compensation			667		-72		-3,007
	Tax income (expense) from prior periods			157		-1,241		44
	Tax free income and tax credits			645		2,174		1,684
	Additional state taxes			-1,133		-511		-909
Change in tax rate			-2,236		-		-
Change in valuation allowance			-2,259		-91		1,493
Other			52		279		-29
Provision for income taxes		$	-49,022	$	-42,718	$	-35,744
The change in tax rate from prior periods of $2,236 at September 30, 2013, predominantly relates to a non-cash remeasurement of deferred tax assets and liabilities resulting from an increase in the local trade tax rate at our principal German operations. The income tax provision at September 30, 2012 includes expenses of $1,733 related to a tax audit in Germany covering fiscal years 2005 until 2009.
In August 2007, a tax law was enacted that may limit the Company's deductibility of interest in Germany (“Zinsschranke”). For the fiscal years ended September 30, 2013 and 2012, the Company's deductibility of interest was not limited as a result of this German tax law.
The components of income before taxes are:
			Year ended		Year ended		Year ended
			September 30,		September 30,		September 30,
			2013		2012		2011
			$'000s
Germany		$	125,262	$	112,963	$	102,693
United States			23,230		16,590		16,236
Other Foreign			49,079		48,770		40,600
		$	197,571	$	178,323	$	159,529
None of the goodwill recognized in the Exchange or in the business combinations completed in any of the periods presented is tax deductible.
The development of the valuation allowance on deferred tax assets over the last three fiscal years is presented below:
				Additions
		Balance		Charged/						Balance
		at		(credited) to		Charged to				at
		Beginning		Cost and		Other				End of
		of Period		Expenses		Accounts		Deductions		Period
		$'000s
Valuation allowance deferred tax asset
For the year ended September 30, 2013	$	876	$	-	$	2,373	$	-	$	3,249
For the year ended September 30, 2012		1,031		-		116		271		876
For the year ended September 30, 2011		2,208		-		-		1,177		1,031
The company makes no provision for deferred U.S. income taxes on undistributed foreign earnings and profits because as of September 30, 2013, it remained management's intention to continue to indefinitely reinvest these amounts in foreign operations. These earnings relate to ongoing operations and, as of September 30, 2013, the approximate amount of undistributed foreign earnings amounted to $409 million. Because of the availability of U.S. foreign tax credits as well as other factors, it is not practicable to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely.
As of September 30, 2013 and 2012, the Company had no unrecognized tax benefits.
With limited exception, the Company and its subsidiaries are no longer subject to U.S. federal, state and local or non-U.S. income tax audits (including Germany) by taxing authorities for tax returns filed with respect to periods prior to fiscal year 2009.
The Company classifies interest and penalties associated with income taxes as interest and other operating expense, respectively. Amounts of interest or penalties have not been material in any period.

Accrued_liabilities_and_deferr

Accrued liabilities and deferred income	12 Months Ended
	Sep. 30, 2013
Accrued Liabilites And Deferred Income [Abstract]	'
Accrued liabilites and deferred income	'
	11. Accrued Liabilities and Deferred Income
				September 30,		September 30,
				2013		2012
				$'000s
		Employee benefits (e. g. bonuses, vacation,
		overtime, holiday payment)	$	43,455	$	34,678
		Product warranty		9,694		8,482
		Customer rebates and bonuses		35,323		13,752
		Other provisions and liabilities		52,125		40,703
		Deferred income		21,744		20,460
			$	162,341	$	118,075

Shortterm_debt_and_current_por

Short-term debt and current portion of long-term debt	12 Months Ended
	Sep. 30, 2013
Short Term Debt And Current Portion Of Long Term Debt [Abstract]	'
Short-term debt and current portion of long-term debt	'
	12. Short-Term Debt and Current Portion of Long-Term Debt
	The components of short-term debt are as follows:
				September 30,		September 30,
				2013		2012
				$'000s
		Accrued interest on long-term debt		270		270
		Other short-term debt		177		208
			$	447	$	478

Longterm_debt

Long-term debt	12 Months Ended
	Sep. 30, 2013
Long Term Debt [Abstract]	'
Long-term debt	'
	13. Long-Term Debt
				September 30,		September 30,
				2013		2012
				$'000s
		Bank loans:
		New Senior Term Loan ("Facility A" Term Loan,
		variable rate) repayable in two installments in November 2015 and November 2016		75,270		75,270
		Actual interest rate as of September 30, 2013 - Tranche A2: 2.88%
		Actual interest rate as of September 30, 2012 - Tranche A2: 2.88%
				75,270		75,270
		Less current portion		270		270
			$	75,000	$	75,000
	The average annual interest rate for the variable rate senior term loans was 2.88% and 2.27% for the fiscal years ended September 30, 2013 and 2012, respectively.
	The table below reflects the contractual maturity dates of the various borrowings as of September 30, 2013:
		Year ending September 30,
		$'000s
		2014			$	447
		2015				-
		2016				22,500
		2017				52,500
		2018				-
					$	75,447
	Senior Term Loans
	New Senior Facilities Agreement
	On November 14, 2011, the Company entered into a new senior facilities agreement (the “New Senior Facilities Agreement”) with Sirona Dental Systems, Inc. and all significant subsidiaries of Sirona as original borrowers and original guarantors. As of November 16, 2011, Sirona fully repaid its obligations under the Prior Senior Facilities Agreement. Initial borrowings under the New Senior Facilities Agreement were used to retire the outstanding borrowings under the Company's previous credit facilities.
	The New Senior Facilities Agreement includes: (1) a term loan in an aggregate principal amount of $75 million (the "Facility A Term Loan") to Sirona or Sirona Dental, as borrower; (2)  a 120 million Euro revolving credit facility (“Revolving Facility B”) available to Sirona Dental Systems GmbH and Sirona Dental Services GmbH, as initial borrowers; and (3)  a $100 million revolving credit facility (“Revolving Facility C”) available to Sirona or Sirona Dental, as initial borrowers. The Revolving Facility B is available for borrowing in Euro or any other freely available currency agreed to by the facility agent. The facilities are made available on an unsecured basis. Subject to certain limitations, each European guarantor guarantees the performance of each European borrower, except itself, and each U.S. guarantor guarantees the performance of each U.S. borrower, except itself. There are no cross-border guarantees.
	Of the amount borrowed under the Facility A Term Loan, 30% is due on November 16, 2015, and the balance is due on November 16, 2016. The loans under the New Senior Facilities Agreement bear interest of EURIBOR, for Euro-denominated loans, and LIBOR for the other loans, plus an initial margin of 160, 85 and 110 basis points for the Facility A Term Loan, Revolving Facility B and Revolving Facility C, respectively. As of September 30, 2013, the Company had not drawn any available funds under Revolving Facility B or Revolving Facility C.
	The New Senior Facilities Agreement contains a margin ratchet. Pursuant to this provision, which will apply from March 31, 2012 onwards, the applicable margin will vary depending on the Company's leverage multiple (i.e. the ratio of consolidated total net debt to consolidated adjusted EBITDA as defined in the new Senior Facilities Agreement) between 160 basis points and 215 basis points for the Facility A Term Loan, 85 basis points and 140 basis points for the Revolving Facility B, and 110 basis points and 165 basis points for the Revolving Facility C.
	The New Senior Facilities Agreement contains restrictive covenants that limit Sirona's ability to make loans, to incur additional indebtedness, and to make disposals, subject to agreed-upon exceptions. The Company has agreed to certain financial debt covenants in relation to the financing. The covenants stipulate that the Company must maintain certain ratios in respect of consolidated total net debt to consolidated adjusted EBITDA. If the Company breaches these covenants, the loans will be become repayable on demand.
	On November 16, 2011, Sirona entered into 5-year payer interest rate swaps to fully hedge its 3-month LIBOR exposure for the Facility A Term Loan. The terms of the swap reflect the term structure of the underlying loan. The effective nominal interest rate is 1.2775% plus the applicable margin. Settlement of the swaps is required on a quarterly basis.
	Debt issuance costs of $2.8 million were incurred in relation to the financing in November 2011 and have been capitalized as deferred charges and are amortized using the effective interest method over the term of the loans.
	Prior Senior Facilities Agreement
	On November 22, 2006, Sirona Dental Systems, Inc. entered into a Senior Facilities Agreement (the "Prior Senior Facilities Agreement") as original guarantor, with all significant subsidiaries of Sirona as original borrowers and original guarantors. Initial borrowings under the Prior Senior Facilities Agreement plus excess cash were used to retire the outstanding borrowings under the Company's previous credit facilities.
	The senior debt repayment tranche originally scheduled for November 24, 2011 was repaid on November 16, 2011 in connection with the Company's New Senior Facilities Agreement.

Deferred_income

Deferred income	12 Months Ended
	Sep. 30, 2013
Deferred Income [Abstract]	'
Deferred income	'
	14. Deferred Income
	On June 30, 2005, Sirona and its largest distributor, Patterson, amended the terms of an existing distribution agreement to extend Patterson's rights as exclusive distributor of certain Sirona products within the U.S. and Canada from October 1, 2007 through September 30, 2017. As consideration for the extension of its exclusivity rights, Patterson made a one-time payment of $100 million to Sirona in July 2005. Sirona recorded the full amount of the payment as deferred income and started amortizing the amount on a straight-line basis over ten years on October 1, 2007. Sirona accounts for the deferred income related to the Patterson payment as a monetary liability. The deferred income is amortized and recognized as other operating income on a straight line over the term of the contract ($10 million per year). The current portion of deferred income is reported within Accrued liabilities and deferred income in the consolidated balance sheets. Effects of remeasurement of the amount from U.S. Dollar to Euro are reflected currently in the statement of income. Sirona recognized a $1.9 million foreign currency transaction gain in the fiscal year ended September 30, 2013, a $2.6 million foreign currency transaction loss in the fiscal year ended September 30, 2012, and a $0.5 million foreign currency transaction loss in the fiscal year ended September 30, 2011. Sirona recognized $10.0 million of the Patterson deferred income in the consolidated statements of income for the fiscal years ended September 30, 2013, 2012, and 2011.

Income_per_Share

Income per Share	12 Months Ended
	Sep. 30, 2013
Income Per Share [Abstract]	'
Income per share	'
	15. Income per Share
	The computation of basic and diluted income per share is as follows:
				Year ended		Year ended		Year ended
				30-Sep-13		30-Sep-12		30-Sep-11
				$'000s (except for share amounts)
		Net income attributable to Sirona Dental Systems, Inc. shareholders	$	146,745	$	133,832	$	121,793
		Weighted average shares outstanding - basic		54,979,044		55,524,188		55,735,422
		Dilutive effect of stock-based compensation		1,234,948		1,231,208		1,557,574
		Weighted average shares outstanding - diluted		56,213,992		56,755,396		57,292,996
		Net income per share
		Basic	$	2.67	$	2.41	$	2.19
		Diluted	$	2.61	$	2.36	$	2.13
	There were no stock options excluded from the computation of diluted earnings per share for the fiscal years ended September 30, 2013, 2012 and 2011.

Commitments_and_contingencies

Commitments and contingencies	12 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
Commitments and contingencies	'
	16. Commitments and Contingencies
	Operating Lease Commitments
	The Company leases certain buildings, vehicles and IT equipment from unrelated third parties. The leases are non-cancellable and have terms of more than one year. Leasing expense for the last three fiscal years was as follows:
				Leasing Expense
				$'000s
		Fiscal year ended September 30, 2013	$	16,358
		Fiscal year ended September 30, 2012		14,888
		Fiscal year ended September 30, 2011		12,783
	In July 2005, Sirona entered into a sale and leaseback agreement regarding unused land on the site of the major facility in Bensheim. The land was sold to an unrelated property development company, who constructed an office building on the site based on Sirona's specifications. Sirona leased the property from the property development company through an 18-year lease. Under the terms of the lease, rent is fixed at Euro 1,202 ($1,623 at the U.S. Dollar/Euro exchange rate of September 30, 2013) per annum until the end of 2013. After 2013, rent is subject to adjustment according to an inflation index. Rental payments started in April 2007 when the building was ready for occupancy. The land remains an asset on Sirona's balance sheet and the building is accounted for as an operating lease.
	Furthermore, the Company rents space in New York, Charlotte (USA), Salzburg (Austria) and other locations.
	Future minimum lease payments under non-cancelable operating lease agreements as of
	September 30, 2013 are as follows:
		Year ending September 30,
				$'000s
		2014	$	13,499
		2015		11,370
		2016		9,098
		2017		7,428
		2018		5,902
		Thereafter		18,186
			$	65,483
	Unconditional Purchase Commitments
	As of September 30, 2013, the Company had unconditional purchase commitments of $14,184, mainly for purchases of raw material and components, which are due over a period of from one to three years.
	Contingencies
	The Company may be involved in lawsuits, claims, investigations and proceedings, including patent and commercial matters that arise in the ordinary course of business. At September 30, 2013, there are no such matters pending that the Company expects to be material in relation to its business, consolidated financial position, results of operations or cash flows.

Product_Warranty

Product Warranty	12 Months Ended
	Sep. 30, 2013
Product Warranty [Abstract]	'
Product warranty	'
	17. Product Warranty
	The following table provides the changes in the product warranty accrual for the fiscal years ended September 30, 2013 and 2012:
				Year ended		Year ended
				September 30,		September 30,
				2013		2012
				$'000s
		Balance at beginning of the period	$	8,482	$	8,735
		Accruals for warranties issued during the period		19,118		17,726
		Warranty settlements made during the period		-18,277		-17,651
		Translation adjustment		371		-328
		Balance at end of the period	$	9,694	$	8,482

Interest

Interest	12 Months Ended
	Sep. 30, 2013
Interest [Abstract]	'
Interest	'
	18. Interest
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
		Interest expense	$	-3,975	$	-4,603	$	-5,763
		Interest income		565		836		1,880
			$	-3,410	$	-3,767	$	-3,883

Pension_Plans

Pension Plans	12 Months Ended
	Sep. 30, 2013
Pension Plans [Abstract]	'
Pension plans	'
	19. Pension Plans
	Defined Benefit Plans
	In Germany, the Company traditionally had an unfunded defined benefit pension plan whose benefits are based primarily on years of service and wage and salary group. As of January 1, 2001, the Company replaced its unfunded defined benefit pension plan with a new defined contribution plan. All new hires after that date only receive defined contributions to a pension plan based on a percentage of the employee's eligible compensation. However, due to grandfathering provisions for certain existing employees hired before that date, the Company continues to be obligated to provide pension benefits which are at a minimum equal to benefits that would have been available under the terms of the traditional defined benefit plans (Grandfathered Benefit). The Grandfathered Benefit and contributions to the Company's pension plan made for those employees after January 1, 2001 are included in the disclosures for defined benefit plans. The Company accounts for the Grandfathered Benefit by recognizing the higher of the defined contribution obligation or the defined benefit obligation for the minimum benefit. As of September 30, 2013 and 2012, contributions made through the defined contribution plan for those employees are adequate to cover the Grandfathered Benefit obligation. Therefore, the Company accounts for that portion of its pension obligation as a fully funded plan with a funded status of zero.
	In addition, the Company offers defined contribution benefits under the terms of a Section 401(k) plan to employees in the U.S.
	The Company uses an actuarial measurement date of September 30.
	Change in the projected benefit obligation and plan assets for all of the Company's defined benefit plans is as follows:
				Year ended		Year ended
				September 30,		September 30,
				2013		2012
				$'000s
		Projected benefit obligation at beginning
		of period	$	74,712	$	62,255
		Service cost		1,426		1,069
		Interest cost		2,127		2,483
		Actuarial (gain)/loss		1,149		13,535
		Investment earnings		222		409
		Benefits paid		-2,568		-2,303
		Currency translation		3,404		-2,736
		Projected benefit obligation at end of period		80,472		74,712
		Fair value of plan assets at beginning of
		period		13,083		12,578
		Actual return on plan assets		222		409
		Employer's contribution		1,223		857
		Benefits paid		-648		-218
		Currency Translation		607		-543
		Fair value of plan assets at end of period		14,487		13,083
		Funded status	$	-65,985	$	-61,629
	Components of net periodic benefit costs are as follows:
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
		Service cost, net	$	203	$	212	$	578
		Interest cost		2,127		2,483		2,510
		Amortization of actuarial gains		128		-310		-164
		Net periodic benefit cost	$	2,458	$	2,385	$	2,924
	The accumulated benefit obligation as of September 30, 2013 and 2012 was $64,978 and $60,614, respectively.
	To the extent the defined benefit obligation is recognized for the Grandfathered Benefit, the long-term estimated rate of return on plan assets is 3.56% (2012: 4.16%) per annum. This rate was based on an appropriate long-term rate for the plan assets held.
	The benefits expected to be paid in cash of the following five years, and in aggregate for the fiscal years thereafter, are as follows:
		Year ending September 30,
		$'000s
		2014	$	3,835
		2015		2,886
		2016		3,131
		2017		2,887
		2018		3,231
		5 Years thereafter		17,092
			$	33,062
	The contributions expected to be made in each of the following five years and in aggregate thereafter are as follows:
		Year ending September 30,
		$'000s
		2014	$	1,277
		2015		1,281
		2016		1,260
		2017		1,240
		2018		1,221
		5 Years thereafter		11,835
			$	18,114
	Weighted-average assumptions used to determine benefit obligations (current-year rate) and net periodic benefit costs (prior-year rate) are as follows:
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
		Discount rate		3.40%		3.50%		5.25%
Plan assets consist of insurance policies with a guaranteed minimum return by the insurance company and an excess profit participation feature for a portion of the benefits. Sirona pays the premiums on the insurance policies but does not manage the investment of the funds; the insurance company makes all decisions on investment of funds, including the allocation to asset groups. The fair value of the plan assets such as equity securities, fixed-income investments, and others is based on the cash surrender values reported by the insurance company.
Defined Contribution Plans
The Company made contributions to the U.S. plans of $801 and $688 for the fiscal years ended September 30, 2013 and 2012, respectively. The Company is obligated to match employee contributions as defined in the plans.
Contributions were also made to foreign plans of $931 and $747 for the fiscal years ended September 30, 2013 and 2012, respectively.

Net_Other_Operating_Income_and

Net Other Operating Income and Restructuring Costs	12 Months Ended
	Sep. 30, 2013
Net Other Operating Income and Restructuring Costs [Abstract]	'
Net Other Operating Income and Restructuring Costs	'
	20. Net Other Operating Income
	The components of net other operating income are as follows:
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
		Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$	10,000	$	10,000	$	10,000
		Gain/(Loss) from patent infringement settlement		4,414		-		-
			$	14,414	$	10,000	$	10,000
	The gain from a patent infringement settlement for the fiscal year ended September 30, 2013, represents amounts received related to prior years.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Strategies	12 Months Ended
	Sep. 30, 2013
Derivative Instruments And Hedging Strategies [Abstract]	'
Derivative Instruments and Hedging Strategies	'
	21. Derivative Instruments and Hedging Strategies
	Our operations are exposed to market risks from changes in foreign currency exchange rates and interest rates. In the normal course of business, these risks are managed through a variety of strategies, including the use of derivatives.
	Interest Rate Risk
	The Company is exposed to interest rate risk associated with fluctuations in the interest rates on its variable interest rate debt. In order to manage this risk, the Company enters into interest rate swap agreements, when appropriate, based upon market conditions.
	Foreign Currency Exposure
	Although the U.S. Dollar is Sirona's reporting currency, it conducts its business in many currencies, and its functional currencies vary depending on the country of operation, which exposes the Company to market risk associated with foreign currency exchange rate movements. The Company's policy generally is to hedge major foreign currency transaction exposure through foreign exchange forward contracts.
	Cash Flow Hedges
	Interest Rate
	The Company uses interest rate swaps to convert a portion of its debt's variable interest rate to a fixed interest rate. Interest rate swaps have been established for 100% of the interest for the Facility A Term Loan under the New Senior Facilities Agreement until November 2016. The interest rate swaps fix the LIBOR element of interest payable on 100% of the principal amount of the Facility A Term Loan for defined three month interest periods over the entire term of the loan. The defined interest rates fixed for each three month interest period range from 1.270% to 1.285%. Settlement of the swaps is required on a quarterly basis. These swaps are designated as hedging instruments under ASC 815. The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes.
	Under the Prior Senior Facilities Agreement, interest rate swaps were established for 66.6% of the interest until March 2010. These swaps expired on March 31, 2010 and were not renewed. The interest rate swaps fixed the LIBOR or EURIBOR element of interest payable on 66.7% of the principal amount of the loans for defined twelve and thirteen month interest periods over the lifetime of the swaps, respectively. The defined interest rates fixed for each twelve or thirteen month interest period ranged from 3.50% to 5.24%. Settlement of the swaps was required on a quarterly basis. These swaps were considered to be economic hedges and not designated as hedging instruments under ASC 815.
	Foreign Currency
	The Euro is the functional currency for many of Sirona's subsidiaries, including its primary sales and manufacturing operations in Germany. During the periods under review, exchange rates fluctuated significantly, thereby impacting Sirona's financial results. In order to hedge portions of the transactional exposure to fluctuations in exchange rates, based on forecasted and firmly committed cash flows, Sirona enters into foreign currency forward (different from functional currency) contracts (currently: USD, AUD, and JPY). These forward foreign currency contracts are intended to reduce short-term effects of changes in exchange rates. The Company enters into forward contracts that are considered to be economic hedges but which are not considered hedging instruments under ASC 815. As of September 30, 2013 and 2012, these contracts had notional amounts totaling $ 38.1 million and $ 34.3, respectively. These agreements are relatively short-term (generally six months).
	The fair value carrying amount of the Company's derivative instruments at September 30, 2013 is described in Note 22 Fair Value Measurements.
	The following tables summarize the impact of gains and losses from the fair value changes of the Company's derivative instruments reported in our consolidated statement of income for the fiscal years ended September 30, 2013 and 2012:
	Derivatives Designated as Cash Flow Hedging
				Year ended September 30, 2013		Year ended September 30, 2012		Year ended September 30, 2011
				Amount of (Gain)/Loss Recognized in Accumulated Other Comprehensive Income		Amount of (Gain)/Loss Recognized in Accumulated Other Comprehensive Income		Amount of (Gain)/Loss Recognized in Accumulated Other Comprehensive Income
				$'000s
	Interest rate swap contracts		$	-970	$	2,096	$	-
				Year ended September 30, 2013		Year ended September 30, 2012		Year ended September 30, 2011
		Location of (Gain)/Loss Recognized in Income on Derivative		Ineffective portion Recognized in Income		Ineffective portion Recognized in Income		Ineffective portion Recognized in Income
				$'000s
	Interest rate swap contracts	(Gain)/loss on derivative instruments, net	$	-	$	2	$	-
	Derivatives Not Designated as Hedging
				Year ended September 30, 2013		Year ended September 30, 2012		Year ended September 30, 2011
		Location of (Gain)/Loss Recognized in Income on Derivative		Amount of (Gain)/Loss Recognized in Income on Derivative		Amount of (Gain)/Loss Recognized in Income on Derivative		Amount of (Gain)/Loss Recognized in Income on Derivative
				$'000s
	Foreign exchange contracts	(Gain)/loss on derivative instruments, net		-421		-1,963		3,302
	Total		$	-421	$	-1,963	$	3,302

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Sep. 30, 2013
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	22. Fair Value Measurements
	The Company applies the provisions of ASC 820, Fair Value Measurements and Disclosures, for assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded or disclosed at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and the credit risk of the Company and counterparties to the arrangement.
	ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is available and significant to the fair value measurement. ASC 820 establishes and prioritizes the following three levels of inputs that may be used to measure fair value:
	Level 1 - Quoted prices in active markets for identical assets or liabilities.
	Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Inputs that are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability.
	Assets/Liabilities Measured at Fair Value on a Recurring Basis
	The following table presents the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2013 and 2012:
			30-Sep-13
			Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Total
					Foreign Exchange
		$'000s
	Assets
	Cash Equivalents (money market funds)	$	31,317	$	-	$	-	$	31,317
	Derivative Assets		-		917		-		917
	Liabilities
	Derivative Liabilities	$	-	$	-59	$	-	$	-59
	Business Acquisition-related liabilities		-		-		-13,407		-13,407
	Total	$	31,317	$	858	$	-13,407	$	18,768
			30-Sep-12
			Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Total
					Foreign Exchange
		$'000s
	Assets
	Cash Equivalents (money market funds)	$	84,216	$	-	$	-	$	84,216
	Derivative Assets		-		730		-		730
	Liabilities
	Derivative Liabilities	$	-	$	-356	$	-	$	-356
	Business Acquisition-related liabilities		-		-		-7,864		-7,864
	Total	$	84,216	$	374	$	-7,864	$	76,726
	The fair value of the business acquisition-related liabilities as of September 30, 2013 was $13.4 million. The change in fair value was primarily due to the acquisition of a technology company in the first quarter of 2013 of $5.6 million, with the remaining net change in fair value of $(0.1) million recorded in other (income)/expense in the income statement for the fiscal year ended September 30, 2013.
	In the Company's September 30, 2013, Consolidated Balance Sheet derivative assets and derivative liabilities are classified as prepaid expenses and other current assets and accrued liabilities and deferred income, respectively.
	The Company did not elect the fair value option for any other eligible financial instruments.

Segment_Reporting

Segment Reporting	12 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment reporting	'
	23. Segment Reporting
	Sirona manages its business on both a product and geographic basis and has four reporting segments; Dental CAD/CAM Systems, Imaging Systems, Treatment Centers, and Instruments. There are two regional sales organizations, USA and Other World Markets, which distribute Sirona's products globally through a network of independent distributors or our own sales and service infrastructure to dental practices, clinics and laboratories. The Electronic Center is a shared facility that manufactures electronic components and provides services for all Sirona segments, and to a very limited extent, external parties. Further shared functions including customer service, logistics, site management, IT and administration are operated centrally.
	Description of the Company's Segments
	Dental CAD/CAM Systems
	Dental CAD/CAM Systems products comprise CAD/CAM in-office systems for the dentist (CEREC) as well as CAD/CAM systems for the laboratories, such as inLab, inEOS and a central manufacturing service for copings and bridge-frameworks. The CEREC system allows dentists to prepare restorations in an ''out-of-mouth pre-shaped' process and insert them into the patient's mouths during a single appointment.
	Imaging Systems
	Imaging systems products comprise a broad range of equipment for diagnostic imaging in the dental practice, using digital technologies. Sirona has developed a broad range of imaging systems for 2D and 3D panoramic and intra-oral applications.
	Treatment Centers
	Sirona's treatment centers comprise a broad range, from standard dentist chairs to sophisticated centers with integrated diagnostic, hygiene and ergonomic functionalities, such as Teneo, Sinius, C8+, as well as specialist centers used for training purposes.
	Instruments
	Sirona offers a wide range of handpiece products, encompassing handheld and power-operated handpieces for cavity preparation, endodontics, periodontology and prophylaxis. The handpieces are supplemented by multi-function tips, supply and suction hoses, as well as care and hygiene systems for handpiece preparation. Sirona's handpieces are often sold as complete packages in combination with treatment centers. The division also supplies parts for other divisions, especially Treatment Units (OEM turbines and tubes) and CAD/CAM Systems.
	Segment Results
	The following tables reflect the results of the Company's reportable segments under the Company's management reporting system. The segment performance measure used to monitor segment performance is gross profit (''Segment Performance Measure'') excluding the impact of the MDP Transaction and the Exchange. This measure is considered by management to better reflect the performance of each segment as it eliminates the need to allocate centrally incurred costs and significant purchase accounting impacts that the Company does not believe are representative of the performance of the segments. Furthermore, the Company monitors performance geographically by region. As the Company manages its business on both a product and a geographical basis, U.S. GAAP requires segmental disclosure based on product information.
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
	Revenue External
	Dental CAD/CAM Systems		$	409,328	$	334,539	$	306,743
	Imaging Systems			378,042		343,528		319,774
	Treatment Centers			210,666		197,144		183,879
	Instruments			103,455		102,471		102,275
	Total			1,101,491		977,682		912,671
	Electronic center and corporate			0		1,669		1,195
	Total		$	1,101,491	$	979,351	$	913,866
	Revenue Internal
	Imaging Systems			0		20		17
	Treatment Centers			6		6		21
	Instruments			12,822		11,832		11,218
	Intercompany elimination			-12,828		-11,858		-11,256
	Total			0		0		0
	Electronic center and corporate			0		22,452		24,917
	Intercompany elimination			0		-22,452		-24,917
	Total		$	0	$	0	$	0
	Revenue Total
	Dental CAD/CAM Systems		$	409,328	$	334,539	$	306,743
	Imaging Systems			378,042		343,548		319,791
	Treatment Centers			210,672		197,150		183,900
	Instruments			116,277		114,303		113,493
	Total			1,114,319		989,540		923,927
	Electronic center and corporate			0		24,121		26,111
	Total		$	1,114,319	$	1,013,661	$	950,038
	Segment performance measure
	Dental CAD/CAM Systems		$	276,672	$	233,829	$	214,133
	Imaging Systems			221,907		199,526		187,375
	Treatment Centers			81,369		79,625		73,179
	Instruments			43,212		46,966		49,599
	Total			623,160		559,946		524,286
	Electronic center and corporate			5,956		7,804		9,836
	Total		$	629,116	$	567,750	$	534,122
	Depreciation and amortization expense
	Dental CAD/CAM Systems		$	13,533	$	10,260	$	8,131
	Imaging Systems			6,576		6,010		6,191
	Treatment Centers			7,379		7,596		7,180
	Instruments			4,966		3,923		3,479
	Total			32,454		27,789		24,981
	Electronic center and corporate			2,539		2,011		1,251
	Total		$	34,993	$	29,800	$	26,232
	Reconciliation of the Results of the Segment Performance Measure to the Consolidated Statements of
	Operations
	The following table and discussion provide a reconciliation of the total results of operations of the Company's business segments under management reporting to the consolidated financial statements. The differences shown between management reporting and U.S. GAAP for the fiscal year ended September 30, 2013, 2012 and 2011 are mainly due to the impact of purchase accounting. Purchase accounting effects are not included in gross profit as the Company does not believe these to be representative of the performance of each segment.
	Inter-segment transactions are based on amounts which management believes are approximate to the amounts of transactions with unrelated third parties.
				Year ended		Year ended		Year ended
			September 30,		September 30,		September 30,
			2013		2012		2011
			$'000s
Revenue
Total segments (external)		$	1,101,491	$	977,682	$	912,671
Electronic center and corporate			-		1,669		1,195
Consolidated revenue			1,101,491		979,351		913,866
Depreciation and amortization
Total segments			32,454		27,789		24,981
Differences management reporting vs.
US GAAP, electronic center and corporate			43,141		49,960		56,192
Consolidated depreciation and amortization			75,595		77,749		81,173
Segment performance measure
Total segments			623,160		559,946		524,286
Differences management reporting vs.
US GAAP, electronic center and corporate			-31,805		-35,995		-40,634
Consolidated gross profit			591,355		523,951		483,652
Selling, general and administrative expense			332,849		295,659		277,081
Research and development			59,575		52,622		55,530
Provision for doubtful accounts and notes receivable			613		-75		96
Net other operating income			-14,414		-10,000		-10,000
(Gain)/loss on foreign currency transactions, net			12,355		5,873		-5,668
(Gain)/loss on derivative instruments			-421		-1,961		3,302
Interest expense, net			3,410		3,767		3,883
Other (income)/expense			-183		-257		-101
Income before taxes		$	197,571	$	178,323	$	159,529
The adjustments that the Company records to reconcile management reporting to the consolidated financial statements prepared in accordance with U.S. GAAP primarily relate to the exclusion of amortization and depreciation related to the step-up to fair value of the intangible and tangible assets as a result of the MDP Transaction (see Note 9).
The following information is presented in accordance with U.S. GAAP:
					September 30,		September 30,
					2013		2012
					$'000s
Total assets
Dental CAD/CAM Systems				$	834,441	$	657,595
Imaging Systems					469,373		448,360
Treatment Centers					278,147		254,071
Instruments					156,458		134,508
Total				$	1,738,419	$	1,494,534
Goodwill
Dental CAD/CAM Systems				$	315,880	$	296,605
Imaging Systems					201,626		176,702
Treatment Centers					94,092		94,662
Instruments					60,488		63,108
Total				$	672,086	$	631,077
				United		Rest of
		Germany		States		World		Total
		$'000s
Net Sales*
October 1, 2012 to September 30, 2013	$	198,630	$	336,689	$	566,172	$	1,101,491
October 1, 2011 to September 30, 2012		159,327		284,932		535,092		979,351
October 1, 2010 to September 30, 2011		189,005		255,874		468,987		913,866
Long-lived assets**
30-Sep-13	$	159,766	$	6,459	$	22,132	$	188,357
30-Sep-12		130,314		5,434		16,985		152,733
*        Sales are allocated to the country in which the customer is located.
**        Long-lived assets exclude all intangible assets and deferred tax assets.
Concentration of Revenue
A substantial portion of our revenue comes from two distributors accounting for more than 10% of revenues. Patterson Dental accounted for 33%, 29%, and 27% of our total revenues for the fiscal years ending September 30, 2013, 2012, and 2011, respectively. Henry Schein accounted for 14%, 15%, and 17% of our total revenues for the fiscal years ending September 30, 2013, 2012, and 2011, respectively. Together, these two customers represented 47%, 44%, and 44% of our total revenues for the fiscal years ending September 30, 2013, 2012, and 2011, respectively. The accounts receivable from these two customers totaled $73,468, $55,015, and $26,848 for the fiscal as of September 30, 2013, 2012, and 2011, respectively. These revenues were earned across all segments, with a significant portion of revenues with Patterson being earned in the CAD/CAM segment. No other customer accounted for more than 10% of revenues.

Related_Parties

Related Parties	12 Months Ended
	Sep. 30, 2013
Related Parties [Abstract]	'
Related parties	'
	24. Related Parties
	Sirona Holdings S.C.A. Luxembourg (“Luxco”)
	As announced on August 4, 2011, certain existing shareholders in Luxco, a former significant shareholder of Sirona, made cash payments to the chief executive officer and chief financial officer of the Company at that time in connection with their Luxco participation. These payments totaling $6.625 million were made in the fourth quarter of fiscal year 2011, and the Company was required to record a compensation charge as a result. The Company did not use its own funds to make such payments or incur any obligation to refund the amount to those payers.
	In May 2011, Luxco sold all of its remaining 9,747,480 shares in Sirona common stock pursuant to an underwritten follow-on public offering. The Company incurred $0.2 million of costs pursuant to the terms of a registration rights agreement.
	In March 2011, Luxco sold 4,500,000 shares pursuant to an underwritten follow-on public offering. The Company incurred $0.3 million of costs pursuant to the terms of a registration rights agreement.

Unaudited_quarterly_informatio

Unaudited quarterly information	12 Months Ended
	Sep. 30, 2013
Unaudited Quarterly Information [Abstract]	'
Unaudited quarterly information	'
	25. Unaudited Quarterly Information
	The following is a summary of the Company's unaudited quarterly operating results for the fiscal years ended September 30, 2013 and 2012:
			September 30,		June 30,		March 31,		December 31,
			2013		2013		2013		2012
			$'000s (except per share amounts)
	Revenue	$	278,604	$	283,157	$	267,326	$	272,404
	Cost of Sales		135,313		131,670		122,620		120,533
	Gross profit		143,291		151,487		144,706		151,871
	Operating expenses/(income):
	Selling, general and administrative expense		83,372		79,702		83,992		85,783
	Research and development		14,649		15,729		15,102		14,095
	Provision for doubtful accounts and notes receivable		-152		148		547		70
	Net other operating income		-2,500		-2,500		-2,500		-6,914
	Operating income		47,922		58,408		47,565		58,837
	(Gain)/loss on foreign currency transactions, net		1,848		4,510		1,417		4,580
	(Gain)/loss on derivative instruments		-738		-901		2,564		-1,346
	Interest expense, net		822		788		830		970
	Other (income)/expense		-1,227		362		342		340
	Income before taxes		47,217		53,649		42,412		54,293
	Income tax provision		10,741		12,876		10,179		15,226
	Net income		36,476		40,773		32,233		39,067
	Less: Net income attributable to noncontrolling interests		241		223		575		765
	Net income attributable to Sirona Dental Systems, Inc.	$	36,235	$	40,550	$	31,658	$	38,302
	Income per share (attributable to Sirona Dental Systems, Inc. shareholders):
	Net income per share - basic	$	0.66	$	0.74	$	0.58	$	0.7
	Net income per share - diluted	$	0.65	$	0.72	$	0.56	$	0.68
	Weighted average shares - basic		54,980,287		55,002,236		54,928,332		55,004,471
	Weighted average shares - diluted		56,090,777		56,220,901		56,202,296		56,327,927
			September 30,		June 30,		March 31,		December 31,
			2012		2012		2012		2011
			$'000s (except per share amounts)
	Revenue	$	247,364	$	242,007	$	231,864	$	258,116
	Cost of Sales		115,285		113,567		107,215		119,333
	Gross profit		132,079		128,440		124,649		138,783
	Operating expenses/(income):
	Selling, general and administrative expense		76,912		72,434		72,667		73,646
	Research and development		12,606		13,092		13,638		13,286
	Provision for doubtful accounts and notes receivable		-338		-504		728		39
	Net other operating income		-2,500		-2,500		-2,500		-2,500
	Operating income		45,399		45,918		40,116		54,312
	(Gain)/loss on foreign currency transactions, net		-382		2,675		1,350		2,230
	(Gain)/loss on derivative instruments		-2,147		2,686		-2,936		436
	Interest expense, net		984		866		1,014		903
	Other (income)/expense		-529		-218		228		262
	Income before taxes		47,473		39,909		40,460		50,481
	Income tax provision		12,622		9,180		9,305		11,611
	Net income		34,851		30,729		31,155		38,870
	Less: Net income attributable to noncontrolling interests		115		431		634		593
	Net income attributable to Sirona Dental Systems, Inc.	$	34,736	$	30,298	$	30,521	$	38,277
	Income per share (attributable to Sirona Dental Systems, Inc. shareholders):
	Net income per share - basic	$	0.63	$	0.55	$	0.55	$	0.69
	Net income per share - diluted	$	0.62	$	0.53	$	0.54	$	0.67
	Weighted average shares - basic		55,128,904		55,507,312		55,683,043		55,783,648
	Weighted average shares - diluted		56,388,273		56,717,943		56,916,390		57,121,505

Significant_Accounting_Policie

Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2013
Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (''U.S. GAAP''). All amounts are reported in thousands of U.S. Dollars ($), except per share amounts or as otherwise disclosed.
Fiscal year	'
	Fiscal Year
	The Company's fiscal year is October 1 to September 30.
Principles of consolidation	'
	Principles of Consolidation
	The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries.
Use of estimates	'
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from estimates. Some of the more significant estimates include allowances for doubtful accounts, inventory valuation reserves, purchase accounting assumptions, depreciable lives of assets, amortization periods, impairment of long-lived assets, deferred tax asset valuation allowance, discounts to customers, pension reserves, provisions and warranty reserves.
Foreign currency	'
	Foreign Currency
	The functional currency for foreign operations has been determined in all cases to be the local currency. Adjustments resulting from translating foreign functional-currency assets and liabilities are recorded in shareholders' equity as a component of accumulated other comprehensive income. Gains or losses resulting from transactions in other than the functional currency are reflected in the consolidated statements of income, except for intra-group transactions of a long-term nature, which are recorded in shareholders' equity as a component of accumulated other comprehensive income.
Comprehensive income	'
	Comprehensive Income
	In addition to net income, comprehensive income includes other charges or credits to equity other than those resulting from transactions with shareholders. Accumulated other comprehensive income relates to foreign currency translation adjustments related to the Company's foreign subsidiaries, changes in the fair value of cash flow hedges, as well as to the pension adjustment resulting from the application of ASC 715-30, Compensation-Retirement Benefits – Defined Benefit Plans-Pension.
	On October 1, 2012, the Company adopted the new accounting guidance for reporting comprehensive income (“CI”) (ASU 2011-05, Presentation of Comprehensive Income). This new guidance requires that all non-owner changes in shareholders' equity be presented either (1) in a single continuous statement of comprehensive income or (2) in two separate but consecutive statements. As a result, the Company reported all such changes in two separate, consecutive statements: Condensed Consolidated Statements of Income and Condensed Consolidated Statement of Comprehensive Income (“CI Statement”). The Company previously reported these items in its Consolidated Statement of Changes in Equity (“Equity Statement”). As a result of adoption, this detailed information was moved from the Equity Statement to the new and separate CI Statement. The details for these items (category and type of change, current period movements, and related tax effects) are reported separately in Note 5 to the consolidated financial statements. All related disclosures have been adjusted accordingly. Prior year amounts and presentation associated with non-owner changes in shareholders' equity have been adjusted accordingly to conform to the adoption.
Revenue recognition	'
	Revenue Recognition
	The Company's main revenue stream results from the delivery of dental equipment. The Company also enters into revenue arrangements that consist of multiple deliverables of its product and service offerings. Additionally, certain products, primarily in our CAD/CAM and Imaging segments, may contain embedded software that functions together with the product to deliver the product's essential functionality.
	Revenue, net of related discounts and allowances, is recognized when products or equipment have been shipped, when persuasive evidence of the arrangement exists, the price is fixed or determinable, collectability is reasonably assured, title and risk of loss has passed to customers based on the shipping terms, no significant obligations remain, and allowances for discounts, returns, and customer incentives can be reliably estimated. The Company offers discounts to its distributors if certain conditions are met. Discounts and allowances are primarily based on the volume of products purchased or targeted to be purchased by the individual customer or distributor. Discounts are deducted from revenue at the time of sale or when the discount is offered, whichever is later. The Company estimates volume discounts based on the individual customer's historical and estimated future product purchases. Returns of products, excluding warranty related returns, are infrequent and insignificant. Amounts received from customers in advance of product shipment are classified as deferred income until the revenue can be recognized in accordance with the Company's revenue recognition policy.
	Services: Service revenue is generally recognized ratably over the contract term as the specified services are performed. Amounts received from customers in advance of rendering of services are classified as deferred income until the revenue can be recognized upon rendering of those services.
	Extended Warranties: The Company offers its customers an option to purchase extended warranties on certain products. The Company recognizes revenue on these extended warranty contracts ratably over the life of the contract. The costs associated with these extended warranty contracts are recognized when incurred.
	Multiple-Element Arrangements (“MEAs”): Arrangements with customers may include multiple deliverables, including any combination of equipment, services, and extended warranties. The deliverables included in the Company's MEAs are separated into more than one unit of accounting when (i) the delivered equipment has value to the customer on a stand-alone basis, and (ii) delivery of the undelivered service element(s) is probable and substantially in the control of the Company. Arrangement consideration is then allocated to each unit, delivered or undelivered, based on the relative selling price (“RSP”) of each unit of accounting based first on vendor-specific objective evidence (“VSOE”) if it exists and then based on estimated selling price (“ESP”).
	VSOE – In most instances, products are sold separately in stand-alone arrangements. Services are also sold separately through renewals of contracts with varying periods. The Company determines VSOE based on its pricing and discounting practices for the specific product or service when sold separately, considering geographical, customer, and other economic or marketing variables, as well as renewal rates or stand-alone prices for the service element(s).
	ESP – The estimated selling price represents the price at which the Company would sell a product or service if it were sold on a stand-alone basis. When VSOE does not exist for all elements, the Company determines ESP for the arrangement element based on sales, cost and margin analysis, as well as other inputs based on its pricing practices. Adjustments for other market and Company-specific factors are made as deemed necessary in determining ESP.
	After separating the elements into their specific units of accounting, total arrangement consideration is allocated to each unit of accounting according to the nature of the revenue as described above and application of the RSP method. Total recognized revenue is limited to the amount not contingent upon future transactions.
Research and development	'
	Research and Development
	Amounts spent by the Company for research and development (R&D) efforts are recorded as R&D expenses when incurred. R&D costs relate primarily to internal costs for salaries, direct overhead costs and outside vendors. The Company capitalizes costs of equipment used for general R&D if it has alternative future use. The depreciation related to this capitalized equipment is included in the Company's R&D costs. Software development costs incurred prior to the attainment of technological feasibility are considered R&D and are expensed as incurred.
Warranty expense	'
	Warranty Expense
	The Company offers warranties on its products for periods between one and three years. Estimated future warranty obligations related to product sales are charged to operations in the period in which the related revenue is recognized. These estimates are based on historical warranty experience and other relevant information of which the Company is aware. Estimated warranty expenses are recorded as an accrued liability and selling, general and administrative expense.
Shipping and handling costs	'
	Shipping and Handling Costs
	Shipping and handling costs charged to customers are included in revenues, and the associated expense is recorded in cost of sales for all periods presented.
Advertising costs	'
	Advertising Costs
	Advertising costs are expensed as incurred and recorded within selling, general and administrative expense.
Pension benefits	'
	Pension Benefits
	The Company has defined benefit and defined contribution pension plans and an early retirement plan. Sirona recognizes changes in the funded status of its benefit plans, not yet recognized in the income statement, in other comprehensive income until they are amortized as a component of net periodic benefit cost in accordance with the provisions of ASC 715-30, Compensation-Retirement Benefits – Defined Benefit Plans-Pension.
	Pension expense is recognized on an accrual basis over the employee's approximate service periods. Defined benefit pension costs are determined by using an actuarial method, which provides for the deferral of actuarial gains and losses (in excess of a specified corridor) that result from changes in assumptions or actual experience differing from that assumed. Costs relating to changes in the benefit plan as well as the transition obligation are amortized. Disclosure of the components of periodic pension cost is also required. When purchase accounting is applied, pension liabilities are recognized for the projected benefit obligation in excess of plan assets.
	For the defined contribution pension plans, the net pension cost is equal to the contributions required by the plan.
	The Company also has an early retirement plan, Altersteilzeit (''ATZ''), which allows certain German employees who have been accepted into the plan to retire at 60 rather than at the legal retirement age of 67. Eligible employees are those who have attained the age of 59, have completed 12 years of service, and have been accepted to participate in the ATZ plan. Accepted employees join for a period of 2-4 years, during which they work in full active service for 50% of the agreed ATZ plan period, the remaining 50% of the plan period being the passive phase during which the employee does not work.  Alternatively, the employee may work for 50% of the time for the entire agreed ATZ plan period. The alternative actually executed is decided via mutual agreement between Sirona and the employee. During the active service period, the employees receive 50% of their salary plus a bonus payment equal to 35% of their salary, and the remaining 50% of their salary, plus a bonus payment equal to 35% of their salary, is paid during the inactive service period. The Company recognizes the salary component of the ATZ plan over the period from the beginning of the ATZ period to the end of the active service period.
Income taxes	'
	Income Taxes
	Differences between the basis of assets and liabilities for financial statement purposes and for tax return purposes are recorded as deferred tax assets or deferred tax liabilities in the accompanying consolidated financial statements. Deferred taxes represent the tax consequences in future years of these differences at each balance sheet date, based on the enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. The provision (benefit) for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities. A valuation allowance is established when it is more likely than not that the deferred tax assets are not realizable. The effect on deferred tax assets and liabilities of a change in the tax rates is recognized in income as an adjustment to income tax expense in the period that includes the enactment date. See Note 10, “Income Taxes” for additional information.
Cash and cash equivalents	'
	Cash and Cash Equivalents
	All highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Investments in money market funds are carried at fair value. All other cash equivalents are stated at cost, which approximates fair value.
Restricted cash	'
	Restricted Cash
	Restricted cash represents cash balances that are i) pledged as collateral to financial institutions that provide security for prepayments from customers and other bonds or ii) held as security deposits for leased office space.
Accounts receivable	'
	Accounts Receivable
	Accounts receivable are stated at the invoiced amount, less allowances for doubtful accounts, which approximates fair value given their short-term due dates. Collectability of accounts receivable is regularly reviewed and is based upon managements' knowledge of customers and compliance with credit terms. The allowance for doubtful accounts is adjusted based on such evaluation, with the corresponding expense included in the provision for doubtful accounts and notes receivable in the Consolidated Statements of Income. Accounts receivable balances are written off when management deems the balances uncollectible.
Inventory	'
	Inventory
	Inventory is carried at the lower of cost or market value. Cost is determined using standard costing, which approximates the weighted average cost method. In addition to direct material and direct labor costs, certain costs related to the overhead and production expenses are included in inventory. Inventory reserves are provided for risks relating to slow moving, unmarketable, and obsolete items.
Business acquisitions	'
	Business Acquisitions
	The Company acquires businesses as well as partial interests in businesses. Acquired businesses are accounted for using the acquisition method of accounting, which requires that all assets and liabilities are recorded at their respective fair values. Any excess of the purchase price over estimated fair values of net assets is recorded as goodwill. The assumptions made in determining fair value assigned to acquired assets and liabilities as well as asset lives can materially impact the results of operations.
	The Company obtains information during due diligence and through other sources to arrive at respective fair values. Examples of factors and information that the Company uses to determine the fair values include: tangible and intangible asset evaluations and appraisals; evaluations of existing contingencies and liabilities; product line integration information; and information systems compatibilities. If the initial accounting for an acquisition is incomplete by the end of the quarter in which the acquisition occurred, the Company will record a provisional estimate in the financial statements. The provisional estimate will be finalized as soon as information becomes available but no later than one year from the acquisition date.
Investments in companies	'
	Investments in Companies
	Investments in associated companies over which the Company can exercise significant influence but not effective control are accounted for using the equity method. Investments in associated companies over which the Company cannot exercise significant influence or effective control are accounted for at cost.
Property, plant and equipment	'
	Property, Plant and Equipment
	Property, plant, and equipment are recorded at historical cost plus the fair value of asset retirement costs, if any and if reasonably estimable, less accumulated depreciation. Additions, improvements and major renewals, which extend the useful life of the asset, are capitalized; maintenance and repairs are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in current operating income. Development costs for external use software incurred after the establishment of technological feasibility are capitalized and amortized to cost of revenues on a straight-line basis over the expected useful life of the software. Costs of software developed for internal use incurred during the development of the application are capitalized and amortized to operating expense on a straight-line basis over the expected useful life of the software. Prepayments for property, plant, and equipment are classified as property, plant, and equipment and are not depreciated until the assets are received and placed into service.
	The cost of plant and equipment is depreciated using the straight-line method over the following estimated useful lives of the respective assets:
			Minimum Useful Life (years)	Maximum Useful Life (years)
		Buildings	25	50
		Building improvements and leasehold improvements	5	10
		Machinery and technical equipment	3	10
		Software and software licenses	3	5
Finite-lived intangible assets	'
	Finite-Lived Intangible Assets
	Finite-lived intangible assets are amortized according to the pattern in which the economic benefit of the asset is used up over their estimated useful lives, as shown below:
			Minimum Useful Life (years)	Maximum Useful Life (years)
		Patents and licenses	10	13
		Technologies and Dealer Relationships	1	15
Impairment of long-lived and finite-lived assets	'
	Impairment of Long-Lived and Finite-Lived Assets
	Long lived assets held for use by the Company are reviewed for impairment whenever events or circumstances provide evidence that suggests the carrying amount of the asset may not be recoverable. The Company performs ongoing impairment analysis on technology-related intangible assets. Determination of whether an impairment exists is based upon a comparison of the identifiable undiscounted cash flows of the assets or groups of assets to the carrying amount of the assets or groups of assets. If impaired, the resulting charge reflects the excess of the asset's carrying amount over its fair value.
Goodwill and indefinite-lived intangible assets	'
	Goodwill and Indefinite-Lived Intangible Assets
	Goodwill and indefinite lived intangible assets, consisting of certain trademarks and in-process research and development (IPR&D), are not amortized, but are reviewed for potential impairment on an annual basis as of September 30, or whenever events or circumstances indicate that the carrying amount may not be recoverable. First, a qualitative assessment is performed on reporting units to determine if further quantitative impairment testing is necessary. If this qualitative assessment indicates that a possible impairment exists, a quantitative impairment test is performed. Goodwill impairment tests are based upon a comparison of the fair value of the reporting units to their respective carrying amount. If the carrying amount of the reporting unit exceeds its fair value, the goodwill impairment loss is measured as the excess of the carrying amount of goodwill over its implied fair value. If impairment is identified on indefinite-lived intangibles, the resulting charge reflects the excess of the asset's carrying amount over its fair value.
Other non-current assets	'
	Other non-current assets
	Other non-current assets and prepaid expenses include capitalized debt issuance costs. The costs are amortized using the effective interest method.
Derivative financial instruments	'
	Derivative Financial Instruments
	The Company enters into forward foreign currency contracts in order to manage currency risks arising from its forecasted and firmly committed foreign currency denominated cash flows. The Company enters into these contracts to limit the foreign exchange rate risk for periods generally not to exceed six months. The Company also enters into interest rate swaps to manage its interest rates on its long term debt.
	The Company does not utilize financial instruments for speculative purposes. The Company accounts for derivative financial instruments in accordance with ASC 815, Derivatives and Hedging. This Topic prescribes requirements for designation and documentation of hedging relationships and ongoing assessments of effectiveness in order to qualify for hedge accounting. The Company has designated its interest rate swaps as qualifying hedge instruments and therefore applies hedge accounting. The Company has not designated any of its foreign currency derivatives as qualifying for hedge accounting under ASC 815. All derivative instruments are recognized as either assets or liabilities in the consolidated balance sheet at fair value. The fair value of the forward foreign currency contracts and interest rate swaps are included within prepaid and other current assets or current accrued liabilities, depending on whether they are an asset or a liability. The change in fair value is recognized within ''Gains (losses) on derivative instruments'' in the consolidated statement of income for the forward foreign currency contracts and the ineffective portion of the interest rate swaps. The effective portion of interest rate swaps is recognized within “Accumulated other comprehensive income/(loss)” in the consolidated balance sheet.
Fair value of financial instruments	'
	Fair Value of Financial Instruments
	Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, bank loans, foreign currency forward contracts, interest rate swaps, and certain liabilities related to fixed and intangible asset purchases and liabilities for business acquisitions primarily from earn-out features. The carrying values of cash, cash equivalents, accounts receivable, and accounts payable approximate their respective fair values because of the short-term nature of these items. The fair value of the foreign currency forward contracts and interest rate swaps are estimated based on information such as quotes from financial institutions. The fair values of the acquisition-related liabilities are based on discounted valuations of commercial assumptions made by Company management of stipulations governed in the underlying purchase agreements.

Basis_of_presentation_and_summ1

Basis of presentation and summary of significant accounting policies (Tables)	12 Months Ended
	Sep. 30, 2013
Basis Of Presentation And Summary Of Significant Accounting Policies [Abstract]	'
Schedule of advertising costs	'
			Advertising Costs
			$'000s
	Fiscal year ended September 30, 2013	$	39,285
	Fiscal year ended September 30, 2012		34,228
	Fiscal year ended September 30, 2011		33,091
Schedule of estimated useful life of property, plant and equipment	'
			Minimum Useful Life (years)	Maximum Useful Life (years)
		Buildings	25	50
		Building improvements and leasehold improvements	5	10
		Machinery and technical equipment	3	10
		Software and software licenses	3	5
Schedule of estimated useful life of finite-lived intangible assets	'
			Minimum Useful Life (years)	Maximum Useful Life (years)
		Patents and licenses	10	13
		Technologies and Dealer Relationships	1	15

Employee_ShareBased_Compensati1

Employee Share-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2013
Employee Share-Based Compensation [Abstract]	'
Schedule of Black-Scholes assumptions (option pricing)	'
			Year ended		Year ended
			30-Sep-13		30-Sep-12
	Expected Volatility		38.23%		39.17%
	Risk-free rate		0.70%		0.91%
	Expected term		5 years		5 years
	Expected dividends		-		-
Schedule of compensation expense and other information	'
			Year ended		Year ended		Year ended
			30-Sep-13		30-Sep-12		30-Sep-11
			$'000s
	Compensation Expense
	Cost of sales	$	138	$	113	$	136
	Selling, general and administrative (1)		12,537		8,383		7,297
	Research and development		138		127		171
		$	12,813	$	8,623	$	7,604
	(1) For the fiscal year 2013, this includes the compensation charge from the first quarter of $3,764 for the modification of share based awards in connection with the Transition Agreement for the former CEO and Chairman.
			Year ended		Year ended		Year ended
			30-Sep-13		30-Sep-12		30-Sep-11
			$'000s (except where noted)
	Additional Information
	Tax Information
	Income tax benefit recognized for share-based compensation	$	-3,731	$	-2,486	$	-1,948
	Tax benefit realized from share-based compensation	$	-9,799	$	-3,282	$	-11,483
	Future Costs
	Total compensation cost to be recognized in future periods related to outstanding non-vested share-based compensation awards	$	19,599	$	17,718	$	14,818
	Weighted-average period expected for recognition of cost (in years)		2.6		2.6		2.6
Schedule of restricted and performance-based stock unit activity	'
			Year ended September 30, 2013
			Restricted Stock Units				Performance-based Stock Units
			Number of shares		Weighted average market price at grant		Number of shares		Weighted average market price at grant
	Outstanding at beginning of period		585,187	$	38.47		13,000	$	36.78
	Granted		180,036		63.19		-		0
	Vested		-157,039		37.37		-		0
	Forfeited		-37,256		41.49		-		0
	Outstanding at end of period		570,928		46.37		13,000		36.78
			Year ended September 30, 2012
			Restricted Stock Units				Performance-based Stock Units
			Number of shares		Weighted average market price at grant		Number of shares		Weighted average market price at grant
	Outstanding at beginning of period		462,265	$	36.99		13,000	$	36.78
	Granted		216,400		41.15		-		0
	Vested		-75,478		36.26		-		0
	Forfeited		-18,000		41.98		-		0
	Outstanding at end of period		585,187		38.47		13,000		36.78
Schedule of stock option activity	'
			Year ended
			30-Sep-13
					Weighted average
			Number of options		exercise price
	Outstanding at beginning of period		2,157,113	$	17.63
	Granted		154,500		63.45
	Exercised		-512,221		15.49
	Forfeited		-21,290		42.17
	Outstanding at end of period		1,778,102		21.93
	thereof vested and exercisable		1,469,883
			$'000s
	Intrinsic value of options exercised	$	27,339
	Total fair value of options vested	$	2,033
	Aggregate intrinsic value of exercisable stock options	$	75,245
	Weighted average remaining contractual life (in years)		3.3
			Year ended
			30-Sep-12
					Weighted average
			Number of options		exercise price
	Outstanding at beginning of period		2,207,312	$	15.05
	Granted		227,375		40.41
	Exercised		-254,860		15.44
	Forfeited		-22,714		19.12
	Outstanding at end of period		2,157,113		17.63
			$'000s
	Intrinsic value of options exercised	$	8,789
	Total fair value of options vested	$	1,738
	Aggregate intrinsic value of exercisable stock options	$	67,617
	Weighted average remaining contractual life (in years)		4.2
			Year ended
			30-Sep-11
					Weighted average
			Number of options		exercise price
	Outstanding at beginning of period		3,173,403	$	14.04
	Exercised		-950,628		11.72
	Expired		-2,636		19.86
	Forfeited		-12,827		11.83
	Outstanding at end of period		2,207,312		15.05
			$'000s
	Intrinsic value of options exercised	$	35,789
	Total fair value of options vested	$	2,016
	Aggregate intrinsic value of exercisable stock options	$	39,326
	Weighted average remaining contractual life (in years)		4.9

Comprehensive_Income_Tables

Comprehensive Income (Tables)	12 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Schedule of Comprehensive Income (Loss)	'
			September 30,
			2013
			Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain/(loss) from hedging instruments		Total
			$'000s
	Balance at beginning of period	$	-34,017	$	5,478	$	-1,258	$	-29,797
	Current increase / (decrease)		36,715		1,387		970		39,072
	Income tax (expense) / benefit		-		-445		-388		-833
	Balance at end of period		2,698		6,420		-676		8,442
	Less: Other comprehensive income/(loss) attributable to noncontrolling interests, net of tax		-165				-		-165
	Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	2,863	$	6,420	$	-676	$	8,607
			September 30,
			2012
			Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain/(loss) from hedging instruments		Total
			$'000s
	Balance at beginning of period	$	16,007	$	-4,698	$	-	$	11,309
	Current increase / (decrease)		-49,995		14,046		-2,096		-38,045
	Income tax (expense) / benefit		-		-3,870		838		-3,032
	Balance at end of period		-33,988		5,478		-1,258		-29,768
	Less: Other comprehensive income/(loss) attributable to noncontrolling interests, net of tax		29				-		29
	Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	-34,017	$	5,478	$	-1,258	$	-29,797
			September 30,
			2011
			Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain/(loss) from hedging instruments		Total
			$'000s
	Balance at beginning of period	$	21,965	$	-2,264	$	-	$	19,701
	Current increase / (decrease)		-6,041		-3,360		-		-9,401
	Income tax (expense) / benefit				926		-		926
	Balance at end of period		15,924	$	-4,698		-		11,226
	Less: Other comprehensive income/(loss) attributable to noncontrolling interests, net of tax		-83						-83
	Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	16,007	$	-4,698	$	-	$	11,309

Accounts_receivable_Tables

Accounts receivable (Tables)	12 Months Ended
	Sep. 30, 2013
Accounts Receivable [Abstract]	'
Schedule of allowance for doubtful accounts	'
					Additions
			Balance at Beginning of Period		Charged to Cost and Expenses		Charged to Other Accounts		Deductions		Balance at End of Period
			$'000s
	For the year ended September 30, 2013	$	1,408	$	748	$	-	$	568	$	1,588
	For the year ended September 30, 2012		1,868		834		-		1,294		1,408
	For the year ended September 30, 2011		1,681		1,034		-		847		1,868

Inventories_net_Tables

Inventories, net (Tables)	12 Months Ended
	Sep. 30, 2013
Inventories Net [Abstract]	'
Schedule of inventories, net	'
				September 30,		September 30,
				2013		2012
				$'000s
		Finished goods	$	72,621	$	50,878
		Work in progress		14,377		12,349
		Raw materials		37,501		29,561
				124,499		92,788
		Inventory reserve		-15,324		-11,781
			$	109,175	$	81,007

Property_plant_and_equipment_n1

Property, plant and equipment, net (Tables)	12 Months Ended
	Sep. 30, 2013
Property, Plant And Equipment, Net [Abstract]	'
Schedule of property, plant and equipment, net	'
						Accumulated
						Depreciation
				Gross		and Amortization		Net
				$'000s
		As of September 30, 2013
		Land	$	12,643	$	-	$	12,643
		Buildings, building improvements and
		leasehold improvements		40,785		13,379		27,406
		Machinery and technical equipment		186,015		110,956		75,059
		Software and software licenses		70,564		32,395		38,169
		Prepayments for property, plant and equipment		29,460		-		29,460
			$	339,467	$	156,730	$	182,737
						Accumulated
						Depreciation
				Gross		and Amortization		Net
				$'000s
		As of September 30, 2012
		Land	$	12,103	$	-	$	12,103
		Buildings, building improvements and
		leasehold improvements		38,442		10,800		27,642
		Machinery and technical equipment		155,838		94,439		61,399
		Software and software licenses		54,942		20,467		34,475
		Prepayments for property, plant and equipment		7,732		-		7,732
			$	269,057	$	125,706	$	143,351

Intangible_assets_and_goodwill1

Intangible assets and goodwill (Tables)	12 Months Ended
	Sep. 30, 2013
Intangible Assets And Goodwill [Abstract]	'
Schedule of finite-lived intangible assets, future amortization expense	'
			Amortization Expense for Finite-Lived Assets
			$'000s
	Fiscal year ended September 30, 2013		40,603
	Fiscal year ended September 30, 2012		47,949
	Fiscal year ended September 30, 2011		54,941
	Year ending September 30,		Annual Estimated Amortization Expense (Future)
			$'000s
	2014		34,212
	2015		28,183
	2016		21,435
	2017		12,465
	2018		8,657
Schedule of finite-lived intangible assets by major class	'
					Accumulated
			Gross		amortization		Net
			$'000s
	As of September 30, 2013
	Patents & Licenses	$	152,238	$	99,112	$	53,126
	Trademarks		130,760		864		129,896
	Technologies and dealer relationships		491,313		403,154		88,159
	In-process research & development		30,537		-		30,537
			804,848		503,130		301,718
	Goodwill		672,086		-		672,086
	Total intangible assets	$	1,476,934	$	503,130	$	973,804
					Accumulated
			Gross		amortization		Net
			$'000s
	As of September 30, 2012
	Patents & Licenses	$	134,251	$	83,241	$	51,010
	Trademarks		126,245		728		125,517
	Technologies and dealer relationships		434,166		362,478		71,688
	In-process research & development		40,341		-		40,341
			735,003		446,447		288,556
	Goodwill		631,077		-		631,077
	Total intangible assets	$	1,366,080	$	446,447	$	919,633

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2013
Income Taxes [Abstract]	'
Schedule of components of income tax expense/benefit	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
		Current
		Domestic (U.S.)	$	-9,050	$	-8,628	$	-14,638
		Foreign		-55,493		-46,570		-39,473
		Total Current		-64,543		-55,198		-54,111
		Deferred
		Domestic (U.S.)		4,765		4,452		8,571
		Foreign		10,756		8,028		9,796
		Total Deferred		15,521		12,480		18,367
		Total	$	-49,022	$	-42,718	$	-35,744
Schedule of deferred tax assets and liabilities	'
				September 30,		September 30,
				2013		2012
				$'000s
		Employee share-based compensation	$	16,764	$	16,288
		Receivables		2,443		3,011
		Inventory reserve		1,527		1,339
		Property, plant and equipment		-13,718		-11,264
		Intangible assets and goodwill		-122,079		-115,405
		Debt issuance costs		-1,628		-2,044
		Employee benefit accruals		7,997		7,072
		Deferred income		2,234		-353
		Valuation allowances		-3,249		-876
		IC profit elimination		8,638		6,736
		Other		2,603		1,521
		Tax loss carryforward		10,812		8,386
		Net deferred income tax asset (liability)	$	-87,656	$	-85,589
Schedule of summary of tax credit carryforwards	'
		Year of expiration		Losses
				$'000s
		2014	$	111
		2015		1,048
		2016		388
		2017		1,379
		2018		1,557
		2019 - 2034		15,105
		Subtotal		19,588
		Indefinite		15,494
		Total	$	35,082
Schedule of effective income tax rate reconciliation	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
	Income before income taxes		$	197,571	$	178,323	$	159,529
	Reconciliation of provision for income taxes:
	Computed tax provision			-69,782		-66,559		-55,801
	Foreign tax differential			26,524		25,821		23,863
	Nondeductible expenses			-236		-1,298		-1,826
	Permanent differences relating
	to German trade taxes			-1,421		-1,220		-1,143
	Subpart F income net of tax credit			-		-		-113
	Share-based compensation			667		-72		-3,007
	Tax income (expense) from prior periods			157		-1,241		44
	Tax free income and tax credits			645		2,174		1,684
	Additional state taxes			-1,133		-511		-909
	Change in tax rate			-2,236		-		-
	Change in valuation allowance			-2,259		-91		1,493
	Other			52		279		-29
	Provision for income taxes		$	-49,022	$	-42,718	$	-35,744
Schedule of income before income tax, domestic and foreign	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
	Germany		$	125,262	$	112,963	$	102,693
	United States			23,230		16,590		16,236
	Other Foreign			49,079		48,770		40,600
			$	197,571	$	178,323	$	159,529
Schedule of summary of valuation allowance	'
					Additions
			Balance		Charged/						Balance
			at		(credited) to		Charged to				at
			Beginning		Cost and		Other				End of
			of Period		Expenses		Accounts		Deductions		Period
			$'000s
	Valuation allowance deferred tax asset
	For the year ended September 30, 2013	$	876	$	-	$	2,373	$	-	$	3,249
	For the year ended September 30, 2012		1,031		-		116		271		876
	For the year ended September 30, 2011		2,208		-		-		1,177		1,031

Accrued_liabilities_and_deferr1

Accrued liabilities and deferred income (Tables)	12 Months Ended
	Sep. 30, 2013
Accrued Liabilites And Deferred Income [Abstract]	'
Schedule of accrued liabilities and deferred income	'
				September 30,		September 30,
				2013		2012
				$'000s
		Employee benefits (e. g. bonuses, vacation,
		overtime, holiday payment)	$	43,455	$	34,678
		Product warranty		9,694		8,482
		Customer rebates and bonuses		35,323		13,752
		Other provisions and liabilities		52,125		40,703
		Deferred income		21,744		20,460
			$	162,341	$	118,075

Shortterm_debt_and_current_por1

Short-term debt and current portion of long-term debt (Tables)	12 Months Ended
	Sep. 30, 2013
Short Term Debt And Current Portion Of Long Term Debt [Abstract]	'
Schedule of short-term debt	'
				September 30,		September 30,
				2013		2012
				$'000s
		Accrued interest on long-term debt		270		270
		Other short-term debt		177		208
			$	447	$	478

Longterm_debt_Tables

Long-term debt (Tables)	12 Months Ended
	Sep. 30, 2013
Long Term Debt [Abstract]	'
Schedule of long-term debt	'
				September 30,		September 30,
				2013		2012
				$'000s
		Bank loans:
		New Senior Term Loan ("Facility A" Term Loan,
		variable rate) repayable in two installments in November 2015 and November 2016		75,270		75,270
		Actual interest rate as of September 30, 2013 - Tranche A2: 2.88%
		Actual interest rate as of September 30, 2012 - Tranche A2: 2.88%
				75,270		75,270
		Less current portion		270		270
			$	75,000	$	75,000
Schedule Of maturities of long term debt [Table Text Block]	'
		Year ending September 30,
		$'000s
		2014			$	447
		2015				-
		2016				22,500
		2017				52,500
		2018				-
					$	75,447

Income_per_share_Tables

Income per share (Tables)	12 Months Ended
	Sep. 30, 2013
Income Per Share [Abstract]	'
Schedule of income per share	'
				Year ended		Year ended		Year ended
				30-Sep-13		30-Sep-12		30-Sep-11
				$'000s (except for share amounts)
		Net income attributable to Sirona Dental Systems, Inc. shareholders	$	146,745	$	133,832	$	121,793
		Weighted average shares outstanding - basic		54,979,044		55,524,188		55,735,422
		Dilutive effect of stock-based compensation		1,234,948		1,231,208		1,557,574
		Weighted average shares outstanding - diluted		56,213,992		56,755,396		57,292,996
		Net income per share
		Basic	$	2.67	$	2.41	$	2.19
		Diluted	$	2.61	$	2.36	$	2.13

Commitments_and_contingencies_

Commitments and contingencies (Tables)	12 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
Schedule of rent expense from operating leases	'
				Leasing Expense
				$'000s
		Fiscal year ended September 30, 2013	$	16,358
		Fiscal year ended September 30, 2012		14,888
		Fiscal year ended September 30, 2011		12,783
Schedule of future minimum rental payments for operating leases	'
		Year ending September 30,
				$'000s
		2014	$	13,499
		2015		11,370
		2016		9,098
		2017		7,428
		2018		5,902
		Thereafter		18,186
			$	65,483

Product_warranty_Tables

Product warranty (Tables)	12 Months Ended
	Sep. 30, 2013
Product Warranty [Abstract]	'
Schedule of product warranty	'
				Year ended		Year ended
				September 30,		September 30,
				2013		2012
				$'000s
		Balance at beginning of the period	$	8,482	$	8,735
		Accruals for warranties issued during the period		19,118		17,726
		Warranty settlements made during the period		-18,277		-17,651
		Translation adjustment		371		-328
		Balance at end of the period	$	9,694	$	8,482

Interest_Tables

Interest (Tables)	12 Months Ended
	Sep. 30, 2013
Interest [Abstract]	'
Schedule of interest income/expense	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
		Interest expense	$	-3,975	$	-4,603	$	-5,763
		Interest income		565		836		1,880
			$	-3,410	$	-3,767	$	-3,883

Pension_Plans_Tables

Pension Plans (Tables)	12 Months Ended
	Sep. 30, 2013
Pension Plans [Abstract]	'
Schedule of changes in the projected benefit obligation	'
				Year ended		Year ended
				September 30,		September 30,
				2013		2012
				$'000s
		Projected benefit obligation at beginning
		of period	$	74,712	$	62,255
		Service cost		1,426		1,069
		Interest cost		2,127		2,483
		Actuarial (gain)/loss		1,149		13,535
		Investment earnings		222		409
		Benefits paid		-2,568		-2,303
		Currency translation		3,404		-2,736
		Projected benefit obligation at end of period		80,472		74,712
		Fair value of plan assets at beginning of
		period		13,083		12,578
		Actual return on plan assets		222		409
		Employer's contribution		1,223		857
		Benefits paid		-648		-218
		Currency Translation		607		-543
		Fair value of plan assets at end of period		14,487		13,083
		Funded status	$	-65,985	$	-61,629
Schedule of pension plans	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
		Service cost, net	$	203	$	212	$	578
		Interest cost		2,127		2,483		2,510
		Amortization of actuarial gains		128		-310		-164
		Net periodic benefit cost	$	2,458	$	2,385	$	2,924
Schedule of benefits expected to be paid	'
		Year ending September 30,
		$'000s
		2014	$	3,835
		2015		2,886
		2016		3,131
		2017		2,887
		2018		3,231
		5 Years thereafter		17,092
			$	33,062
Schedule of contributions expected to be made	'
		Year ending September 30,
		$'000s
		2014	$	1,277
		2015		1,281
		2016		1,260
		2017		1,240
		2018		1,221
		5 Years thereafter		11,835
			$	18,114
Schedule of weighted-average assumptions used	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
		Discount rate		3.40%		3.50%		5.25%

Net_Other_Operating_Income_and1

Net Other Operating Income and Restructuring Costs (Tables)	12 Months Ended
	Sep. 30, 2013
Net Other Operating Income and Restructuring Costs [Abstract]	'
Schedule of net other operating income	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
		Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$	10,000	$	10,000	$	10,000
		Gain/(Loss) from patent infringement settlement		4,414		-		-
			$	14,414	$	10,000	$	10,000

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Strategies (Tables)	12 Months Ended
	Sep. 30, 2013
Derivative Instruments And Hedging Strategies [Abstract]	'
Schedule of derivative instruments, location and amount of gains and losses	'
	Derivatives Designated as Cash Flow Hedging
				Year ended September 30, 2013		Year ended September 30, 2012		Year ended September 30, 2011
				Amount of (Gain)/Loss Recognized in Accumulated Other Comprehensive Income		Amount of (Gain)/Loss Recognized in Accumulated Other Comprehensive Income		Amount of (Gain)/Loss Recognized in Accumulated Other Comprehensive Income
				$'000s
	Interest rate swap contracts		$	-970	$	2,096	$	-
				Year ended September 30, 2013		Year ended September 30, 2012		Year ended September 30, 2011
		Location of (Gain)/Loss Recognized in Income on Derivative		Ineffective portion Recognized in Income		Ineffective portion Recognized in Income		Ineffective portion Recognized in Income
				$'000s
	Interest rate swap contracts	(Gain)/loss on derivative instruments, net	$	-	$	2	$	-
	Derivatives Not Designated as Hedging
				Year ended September 30, 2013		Year ended September 30, 2012		Year ended September 30, 2011
		Location of (Gain)/Loss Recognized in Income on Derivative		Amount of (Gain)/Loss Recognized in Income on Derivative		Amount of (Gain)/Loss Recognized in Income on Derivative		Amount of (Gain)/Loss Recognized in Income on Derivative
				$'000s
	Foreign exchange contracts	(Gain)/loss on derivative instruments, net		-421		-1,963		3,302
	Total		$	-421	$	-1,963	$	3,302

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2013
Fair Value Measurements [Abstract]	'
Schedule of fair value by Balance Sheet grouping	'
			30-Sep-13
			Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Total
					Foreign Exchange
		$'000s
	Assets
	Cash Equivalents (money market funds)	$	31,317	$	-	$	-	$	31,317
	Derivative Assets		-		917		-		917
	Liabilities
	Derivative Liabilities	$	-	$	-59	$	-	$	-59
	Business Acquisition-related liabilities		-		-		-13,407		-13,407
	Total	$	31,317	$	858	$	-13,407	$	18,768
			30-Sep-12
			Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Total
					Foreign Exchange
		$'000s
	Assets
	Cash Equivalents (money market funds)	$	84,216	$	-	$	-	$	84,216
	Derivative Assets		-		730		-		730
	Liabilities
	Derivative Liabilities	$	-	$	-356	$	-	$	-356
	Business Acquisition-related liabilities		-		-		-7,864		-7,864
	Total	$	84,216	$	374	$	-7,864	$	76,726

Segment_reporting_Tables

Segment reporting (Tables)	12 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of segment reporting information by segment	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
	Revenue External
	Dental CAD/CAM Systems		$	409,328	$	334,539	$	306,743
	Imaging Systems			378,042		343,528		319,774
	Treatment Centers			210,666		197,144		183,879
	Instruments			103,455		102,471		102,275
	Total			1,101,491		977,682		912,671
	Electronic center and corporate			0		1,669		1,195
	Total		$	1,101,491	$	979,351	$	913,866
	Revenue Internal
	Imaging Systems			0		20		17
	Treatment Centers			6		6		21
	Instruments			12,822		11,832		11,218
	Intercompany elimination			-12,828		-11,858		-11,256
	Total			0		0		0
	Electronic center and corporate			0		22,452		24,917
	Intercompany elimination			0		-22,452		-24,917
	Total		$	0	$	0	$	0
	Revenue Total
	Dental CAD/CAM Systems		$	409,328	$	334,539	$	306,743
	Imaging Systems			378,042		343,548		319,791
	Treatment Centers			210,672		197,150		183,900
	Instruments			116,277		114,303		113,493
	Total			1,114,319		989,540		923,927
	Electronic center and corporate			0		24,121		26,111
	Total		$	1,114,319	$	1,013,661	$	950,038
	Segment performance measure
	Dental CAD/CAM Systems		$	276,672	$	233,829	$	214,133
	Imaging Systems			221,907		199,526		187,375
	Treatment Centers			81,369		79,625		73,179
	Instruments			43,212		46,966		49,599
	Total			623,160		559,946		524,286
	Electronic center and corporate			5,956		7,804		9,836
	Total		$	629,116	$	567,750	$	534,122
	Depreciation and amortization expense
	Dental CAD/CAM Systems		$	13,533	$	10,260	$	8,131
	Imaging Systems			6,576		6,010		6,191
	Treatment Centers			7,379		7,596		7,180
	Instruments			4,966		3,923		3,479
	Total			32,454		27,789		24,981
	Electronic center and corporate			2,539		2,011		1,251
	Total		$	34,993	$	29,800	$	26,232
Schedule of reconciliation of operating profit (loss) from segments to consolidated	'
				Year ended		Year ended		Year ended
				September 30,		September 30,		September 30,
				2013		2012		2011
				$'000s
	Revenue
	Total segments (external)		$	1,101,491	$	977,682	$	912,671
	Electronic center and corporate			-		1,669		1,195
	Consolidated revenue			1,101,491		979,351		913,866
	Depreciation and amortization
	Total segments			32,454		27,789		24,981
	Differences management reporting vs.
	US GAAP, electronic center and corporate			43,141		49,960		56,192
	Consolidated depreciation and amortization			75,595		77,749		81,173
	Segment performance measure
	Total segments			623,160		559,946		524,286
	Differences management reporting vs.
	US GAAP, electronic center and corporate			-31,805		-35,995		-40,634
	Consolidated gross profit			591,355		523,951		483,652
	Selling, general and administrative expense			332,849		295,659		277,081
	Research and development			59,575		52,622		55,530
	Provision for doubtful accounts and notes receivable			613		-75		96
	Net other operating income			-14,414		-10,000		-10,000
	(Gain)/loss on foreign currency transactions, net			12,355		5,873		-5,668
	(Gain)/loss on derivative instruments			-421		-1,961		3,302
	Interest expense, net			3,410		3,767		3,883
	Other (income)/expense			-183		-257		-101
	Income before taxes		$	197,571	$	178,323	$	159,529
Schedule of intangible assets and goodwill by segment	'
						September 30,		September 30,
						2013		2012
						$'000s
	Total assets
	Dental CAD/CAM Systems				$	834,441	$	657,595
	Imaging Systems					469,373		448,360
	Treatment Centers					278,147		254,071
	Instruments					156,458		134,508
	Total				$	1,738,419	$	1,494,534
	Goodwill
	Dental CAD/CAM Systems				$	315,880	$	296,605
	Imaging Systems					201,626		176,702
	Treatment Centers					94,092		94,662
	Instruments					60,488		63,108
	Total				$	672,086	$	631,077
Schedule of revenue by geographical area	'
					United		Rest of
			Germany		States		World		Total
			$'000s
	Net Sales*
	October 1, 2012 to September 30, 2013	$	198,630	$	336,689	$	566,172	$	1,101,491
	October 1, 2011 to September 30, 2012		159,327		284,932		535,092		979,351
	October 1, 2010 to September 30, 2011		189,005		255,874		468,987		913,866
	Long-lived assets**
	30-Sep-13	$	159,766	$	6,459	$	22,132	$	188,357
	30-Sep-12		130,314		5,434		16,985		152,733

Unaudited_quarterly_informatio1

Unaudited quarterly information (Tables)	12 Months Ended
	Sep. 30, 2013
Unaudited Quarterly Information [Abstract]	'
Schedule of quarterly financial information	'
			September 30,		June 30,		March 31,		December 31,
			2013		2013		2013		2012
			$'000s (except per share amounts)
	Revenue	$	278,604	$	283,157	$	267,326	$	272,404
	Cost of Sales		135,313		131,670		122,620		120,533
	Gross profit		143,291		151,487		144,706		151,871
	Operating expenses/(income):
	Selling, general and administrative expense		83,372		79,702		83,992		85,783
	Research and development		14,649		15,729		15,102		14,095
	Provision for doubtful accounts and notes receivable		-152		148		547		70
	Net other operating income		-2,500		-2,500		-2,500		-6,914
	Operating income		47,922		58,408		47,565		58,837
	(Gain)/loss on foreign currency transactions, net		1,848		4,510		1,417		4,580
	(Gain)/loss on derivative instruments		-738		-901		2,564		-1,346
	Interest expense, net		822		788		830		970
	Other (income)/expense		-1,227		362		342		340
	Income before taxes		47,217		53,649		42,412		54,293
	Income tax provision		10,741		12,876		10,179		15,226
	Net income		36,476		40,773		32,233		39,067
	Less: Net income attributable to noncontrolling interests		241		223		575		765
	Net income attributable to Sirona Dental Systems, Inc.	$	36,235	$	40,550	$	31,658	$	38,302
	Income per share (attributable to Sirona Dental Systems, Inc. shareholders):
	Net income per share - basic	$	0.66	$	0.74	$	0.58	$	0.7
	Net income per share - diluted	$	0.65	$	0.72	$	0.56	$	0.68
	Weighted average shares - basic		54,980,287		55,002,236		54,928,332		55,004,471
	Weighted average shares - diluted		56,090,777		56,220,901		56,202,296		56,327,927
			September 30,		June 30,		March 31,		December 31,
			2012		2012		2012		2011
			$'000s (except per share amounts)
	Revenue	$	247,364	$	242,007	$	231,864	$	258,116
	Cost of Sales		115,285		113,567		107,215		119,333
	Gross profit		132,079		128,440		124,649		138,783
	Operating expenses/(income):
	Selling, general and administrative expense		76,912		72,434		72,667		73,646
	Research and development		12,606		13,092		13,638		13,286
	Provision for doubtful accounts and notes receivable		-338		-504		728		39
	Net other operating income		-2,500		-2,500		-2,500		-2,500
	Operating income		45,399		45,918		40,116		54,312
	(Gain)/loss on foreign currency transactions, net		-382		2,675		1,350		2,230
	(Gain)/loss on derivative instruments		-2,147		2,686		-2,936		436
	Interest expense, net		984		866		1,014		903
	Other (income)/expense		-529		-218		228		262
	Income before taxes		47,473		39,909		40,460		50,481
	Income tax provision		12,622		9,180		9,305		11,611
	Net income		34,851		30,729		31,155		38,870
	Less: Net income attributable to noncontrolling interests		115		431		634		593
	Net income attributable to Sirona Dental Systems, Inc.	$	34,736	$	30,298	$	30,521	$	38,277
	Income per share (attributable to Sirona Dental Systems, Inc. shareholders):
	Net income per share - basic	$	0.63	$	0.55	$	0.55	$	0.69
	Net income per share - diluted	$	0.62	$	0.53	$	0.54	$	0.67
	Weighted average shares - basic		55,128,904		55,507,312		55,683,043		55,783,648
	Weighted average shares - diluted		56,388,273		56,717,943		56,916,390		57,121,505

Basis_of_presentation_and_summ2

Basis of presentation and summary of significant accounting policies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Advertising costs	'	'	'
Advertising Costs	$39,285	$34,228	$33,091
Pension benefits	'	'	'
Description Of Early Retirement Plan	'The Company also has an early retirement plan, Altersteilzeit (‘‘ATZ’’), which allows certain German employees who have been accepted into the plan to retire at 60 rather than at the legal retirement age of 67. Eligible employees are those who have attained the age of 59, have completed 12 years of service, and have been accepted to participate in the ATZ plan. Accepted employees join for a period of 2-4 years, during which they work in full active service for 50% of the agreed ATZ plan period, the remaining 50% of the plan period being the passive phase during which the employee does not work.  Alternatively, the employee may work for 50% of the time for the entire agreed ATZ plan period. The alternative actually executed is decided via mutual agreement between Sirona and the employee. During the active service period, the employees receive 50% of their salary plus a bonus payment equal to 35% of their salary, and the remaining 50% of their salary, plus a bonus payment equal to 35% of their salary, is paid during the inactive service period. The Company recognizes the salary component of the ATZ plan over the period from the beginning of the ATZ period to the end of the active service period.	'	'
Other non-current assets	'	'	'
Unamortized balance of debt issuance cost	$1,156	$1,681	'
Minimum | Patents & Licenses	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful Life (years)	'10 years	'	'
Minimum | Technologies and dealer relationships	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful Life (years)	'1 year	'	'
Maximum | Patents & Licenses	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful Life (years)	'13 years	'	'
Maximum | Technologies and dealer relationships	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful Life (years)	'15 years	'	'
Buildings | Minimum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful Life (years)	'25 years	'	'
Buildings | Maximum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful Life (years)	'50 years	'	'
Building improvements and leasehold improvements | Minimum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful Life (years)	'5 years	'	'
Building improvements and leasehold improvements | Maximum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful Life (years)	'10 years	'	'
Machinery and technical equipment | Minimum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful Life (years)	'3 years	'	'
Machinery and technical equipment | Maximum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful Life (years)	'10 years	'	'
Software and software licenses | Minimum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful Life (years)	'3 years	'	'
Software and software licenses | Maximum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful Life (years)	'5 years	'	'

Business_Acquisitions_Details

Business Acquisitions (Details) (USD $)	12 Months Ended						12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2013	Oct. 08, 2012
				Development-Stage Entity For Advanced Technology	Development-Stage Entity For Advanced Technology	Development-Stage Entity For Advanced Technology	Technology Company Developing and Manufacturing Dental Products	Technology Company Developing and Manufacturing Dental Products
Business Acquisition, Entity Acquired and Reason for Acquisition [Abstract]	'	'	'	'	'	'	'	'
Business Acquisition, Effective Date of Acquisition	'	'	'	16-May-11	'	'	8-Oct-12	'
Business Acquisition, Percentage of Voting Interests Acquired	'	'	'	100.00%	'	'	100.00%	'
Business Combination, Additional Disclosures	'	'	'	'	'	'	'	'
Fair value of total consideration transferred	$46,636,000	$0	$31,048,000	$31,000,000	'	'	$46,600,000	'
Cost of aquire entity, cash paid	-36,673,000	0	-20,895,000	20,900,000	'	'	36,700,000	'
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	'	'	'	0	'	'	0	'
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	'	'	'	28,000,000	'	'	13,000,000	'
Goodwill	672,086,000	631,077,000	'	'	'	4,900,000	'	'
Fair value at acquisition date	5,419,000	0	10,153,000	'	'	'	'	'
Business Acquisition, Contingent Consideration, at Fair Value	13,400,000	'	'	7,500,000	7,900,000	10,200,000	5,900,000	5,400,000
Changes in fair value of contingent consideration	($100,000)	'	'	($400,000)	'	'	$300,000	'

Employee_ShareBased_Compensati2

Employee Share-Based Compensation (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Jun. 20, 2006

Jun. 20, 2006

Jun. 20, 2006

Sep. 30, 2013

Feb. 25, 2009

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Schick legacy plans

Schick legacy plans

Schick legacy plans

2006 Plan

2006 Plan

2006 Plan

2006 Plan

2006 Plan

2006 Plan

2006 Plan

2006 Plan

2006 Plan

Minimum

Maximum

RSU

RSU

RSU

PSU

PSU

PSU

Stock Options

Minimum

Maximum

Minimum

Maximum

Schick legacy plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation, options vested

'

'

862,220

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation, options outstanding, unvested

'

'

458,179

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation, options expiration date

'

'

20-Jun-16

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation, options conditionally granted to employees upon acquisition

'

'

1,530,000

'

'

'

'

'

'

'

'

'

'

'

Equity incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation, total number of stock options authorized

'

'

'

'

'

'

4,550,000

'

'

'

'

'

'

'

Share-based compensation, number of shares available for future grant

'

'

'

'

'

675,830

'

'

'

'

'

'

'

'

Share-based compensation, award vesting period

'

'

'

'2 years

'4 years

'

'

'

'3 years

'4 years

'3 years

'3 years

'4 years

'4 years

Share-based compensation, options granted in period

154,500

227,375

'

'

'

'

'

180,036

'

'

'

'

'

154,500

Share-based compensation, grants in period weighted average exercised price

$63.45

$40.41

'

'

'

'

'

$63.14

'

'

'

'

'

$63.45

Share-based compensation, options expiration date

'

'

'

'

'

'

'

'10 years

'

'

'10 years

'

'

'10 years

Share-based compensation, weighted average fair value at grant date

'

'

'

'

'

'

'

'

'

'

'

'

'

$21.74

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Volatility

38.23%

39.17%

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free rate

0.70%

0.91%

'

'

'

'

'

'

'

'

'

'

'

'

Expected term

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividends

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

Employee_ShareBased_Compensati3

Employee Share-Based Compensation (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock compensation expense	$12,813	$8,623	$7,604
One-time compensation charge	3,764	'	'
Tax information	'	'	'
Income tax benefit recognized for share-based compensation	-3,731	-2,486	-1,948
Tax benefit realized from share-based compensation	-9,799	-3,282	-11,483
Future costs	'	'	'
Total compensation cost to be recognized in future periods related to outstanding non-vested share-based compensation awards	19,599	17,718	14,818
Weighted-average period expected for recognition of cost (in years)	'2 years 7 months	'2 years 7 months	'2 years 7 months
Cost of sales	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock compensation expense	138	113	136
Selling, general and admistrative	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock compensation expense	12,537	8,383	7,297
Research and development	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock compensation expense	$138	$127	$171

Employee_ShareBased_Compensati4

Employee Share-Based Compensation (Details 2) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
RSU	'	'
Restricted and performance-based stock unit activity	'	'
Outstanding at beginning of period, number of shares	585,187	462,265
Granted, number of shares	180,036	216,400
Vested, number of shares	-157,039	-75,478
Forfeited, number of shares	-37,256	-18,000
Outstanding at end of period, number of shares	570,928	585,187
Outstanding at beginning of period, weighted average market price at grant	$38.47	$36.99
Granted, weighted average market price at grant	$63.19	$41.15
Vested, weighted average market price at grant	$37.37	$36.26
Forfeited, weighted average market price at grant	$41.49	$41.98
Outstanding at end of period, weighted average market price at grant	$46.37	$38.47
PSU	'	'
Restricted and performance-based stock unit activity	'	'
Outstanding at beginning of period, number of shares	13,000	13,000
Granted, number of shares	0	0
Vested, number of shares	0	0
Forfeited, number of shares	0	0
Outstanding at end of period, number of shares	13,000	13,000
Outstanding at beginning of period, weighted average market price at grant	$36.78	$36.78
Granted, weighted average market price at grant	$0	$0
Vested, weighted average market price at grant	$0	$0
Forfeited, weighted average market price at grant	$0	$0
Outstanding at end of period, weighted average market price at grant	$36.78	$36.78

Employee_ShareBased_Compensati5

Employee Share-Based Compensation (Details 3) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Stock option activity	'	'	'
Outstanding at beginning of period, number of options	2,157,113	2,207,312	3,173,403
Granted, number of options	154,500	227,375	'
Exercised, number of options	-512,221	-254,860	-950,628
Expired, number of options	0	0	-2,636
Forfeited, number of options	-21,290	-22,714	-12,827
Outstanding at end of period, number of options	1,778,102	2,157,113	2,207,312
thereof vested and excercisable	1,469,883	'	'
Stock option activity, weighted average exercise price	'	'	'
Outstanding at beginning of period, weighted average exercise price	$17.63	$15.05	$14.04
Granted, weighted average exercise price	$63.45	$40.41	'
Exercised, weighted average exercise price	$15.49	$15.44	$11.72
Expired, weighted average exercise price	$0	$0	$19.86
Forfeited, weighted average exercise price	$42.17	$19.12	$11.83
Outstanding at end of period, weighted average exercise price	$21.93	$17.63	$15.05
Stock option activity, additional disclosures	'	'	'
Intrinsic value of options exercised	$27,339	$8,789	$35,789
Total fair value of options vested	2,033	1,738	2,016
Aggregate intrinsic value of exercisable stock options	$75,245	$67,617	$39,326
Weighted average remaining contractual life (in years)	'3 years 4 months	'4 years 3 months	'4 years 11 months

Comprehensive_Income_Details

Comprehensive Income (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Balance at beginning of period	($29,797)	$11,309	$19,701
Current increase/(decrease)	39,072	-38,045	-9,401
Income tax (expense) / benefit	-833	-3,032	926
Balance at end of period	8,442	-29,768	11,226
Less: Comprehensive income/(loss) attributable to noncontrolling interests, net of tax	-165	29	-83
Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	8,607	-29,797	11,309
Cumulative translation adjustments	'	'	'
Balance at beginning of period	-34,017	16,007	21,965
Current increase/(decrease)	36,715	-49,995	-6,041
Income tax (expense) / benefit	0	0	0
Balance at end of period	2,698	-33,988	15,924
Less: Comprehensive income/(loss) attributable to noncontrolling interests, net of tax	-165	29	-83
Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	2,863	-34,017	16,007
Unrecognized elements of pension cost	'	'	'
Balance at beginning of period	5,478	-4,698	-2,264
Current increase/(decrease)	1,387	14,046	-3,360
Income tax (expense) / benefit	-445	-3,870	926
Balance at end of period	6,420	5,478	-4,698
Less: Comprehensive income/(loss) attributable to noncontrolling interests, net of tax	0	0	0
Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	6,420	5,478	-4,698
Net gain/(loss) from hedging instruments	'	'	'
Balance at beginning of period	-1,258	0	0
Current increase/(decrease)	970	-2,096	0
Income tax (expense) / benefit	-388	838	0
Balance at end of period	-676	-1,258	0
Less: Comprehensive income/(loss) attributable to noncontrolling interests, net of tax	0	0	0
Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	($676)	($1,258)	$0

Accounts_receivable_Details

Accounts receivable (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Balance at Beginning of Period	$1,408	$1,868	$1,681
Deductions	568	1,294	847
Balance at End of Period	1,588	1,408	1,868
Charged to Cost and Expenses	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Additions	$748	$834	$1,034

Inventories_net_Details

Inventories, net (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
In Thousands, unless otherwise specified
Inventories Net [Abstract]	'	'
Finished goods	$72,621	$50,878
Work in progress	14,377	12,349
Raw materials	37,501	29,561
Inventory, gross	124,499	92,788
Inventory reserve	-15,324	-11,781
Inventories, net	$109,175	$81,007

Property_plant_and_equipment_n2

Property, plant and equipment, net (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Gross	$339,467	$269,057	'
Accumulated Depreciation and Amortization	156,730	125,706	'
Net	182,737	143,351	'
Depreciation, Depletion and Amortization	34,993	29,800	26,232
Capitalized Computer Software, Amortization	8,834	6,376	5,360
Land	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Gross	12,643	12,103	'
Accumulated Depreciation and Amortization	0	0	'
Net	12,643	12,103	'
Buildings, building improvements and leashold improvements	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Gross	40,785	38,442	'
Accumulated Depreciation and Amortization	13,379	10,800	'
Net	27,406	27,642	'
Machinery and technical equipment	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Gross	186,015	155,838	'
Accumulated Depreciation and Amortization	110,956	94,439	'
Net	75,059	61,399	'
Prepayments for property, plant and equipment	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Gross	29,460	7,732	'
Accumulated Depreciation and Amortization	0	0	'
Net	29,460	7,732	'
Office space leased under operating leases to third parties	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Gross	1,237	1,385	'
Net	400	497	'
Software and software licences	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Gross	70,564	54,942	'
Accumulated Depreciation and Amortization	32,395	20,467	'
Net	38,169	34,475	'
Payments for expansion of instruments manufacturing capacity	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Gross	$16,900	'	'

Intangible_assets_and_goodwill2

Intangible assets and goodwill (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2013	Jun. 30, 2005
				Sirona Dental Systems Beteiligungs- und Verwaltungs GmbH	Sirona Dental Systems Beteiligungs- und Verwaltungs GmbH
Business Acquisition [Line Items]	'	'	'	'	'
Business Acquisition, Percentage of Voting Interests Acquired	'	'	'	100.00%	100.00%
Assets And Liabilities Valued At Historical Cost Percentage	'	'	'	9.15%	9.15%
Assets And Liabilities Recognized At Fair Value Percentage	'	'	'	90.85%	90.85%
Finite-Lived Intangible Assets, Amortization Expense	$40,603	$47,949	$54,941	'	'
Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]	'	'	'	'	'
2014	34,212	'	'	'	'
2015	28,183	'	'	'	'
2016	21,435	'	'	'	'
2017	12,465	'	'	'	'
2018	$8,657	'	'	'	'

Intangible_assets_and_goodwill3

Intangible assets and goodwill (Details 1) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	$804,848,000	$735,003,000
Accumulated amortization	503,130,000	446,447,000
Intangible Assets, Net (Excluding Goodwill)	301,718,000	288,556,000
Goodwill	672,086,000	631,077,000
Intangible Assets Gross Including Goodwill	1,476,934,000	1,366,080,000
Intangible Assets Accumulated Amortization	503,130,000	446,447,000
Intangible Assets Net Including Goodwill	973,804,000	919,633,000
Change In Goodwill And Intangible Assets [Abstract]	'	'
Goodwill, Acquired During Period	18,167,000	'
Goodwill, Translation Adjustments	22,969,000	'
Finite Lived Intangible Assets Translation Adjustments	8,721,000	'
Excess Tax Benefit, Stock Options, Goodwill Adjustment	-127,000	'
In-process research and development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	30,537,000	40,341,000
Accumulated amortization	0	0
Intangible Assets, Net (Excluding Goodwill)	30,537,000	40,341,000
Change In Goodwill And Intangible Assets [Abstract]	'	'
Acquired Finite Lived Intangible Assets Estimated Cost To Complete Project	3,500,000	'
Acquired Finite Lived Intangible Assets Estimated Percentage Of Completion	40.00%	'
Acquired Finite Lived Intangible Assets Percentage Through Development Phase	55.00%	'
Patents & Licenses	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	152,238,000	134,251,000
Accumulated amortization	99,112,000	83,241,000
Intangible Assets, Net (Excluding Goodwill)	53,126,000	51,010,000
Change In Goodwill And Intangible Assets [Abstract]	'	'
Acquired Finite-lived Intangible Asset, Amount	11,113,000	'
Trademarks	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	130,760,000	126,245,000
Accumulated amortization	864,000	728,000
Intangible Assets, Net (Excluding Goodwill)	129,896,000	125,517,000
Technologies and dealer relationships	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	491,313,000	434,166,000
Accumulated amortization	403,154,000	362,478,000
Intangible Assets, Net (Excluding Goodwill)	88,159,000	71,688,000
Change In Goodwill And Intangible Assets [Abstract]	'	'
Acquired Finite-lived Intangible Asset, Amount	3,079,000	'
Prepayments for intangible assets	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	0	0
Accumulated amortization	0	0
Intangible Assets, Net (Excluding Goodwill)	$0	$0

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Current:	'	'	'	'	'	'	'	'	'	'	'
Domestic (U.S.)	'	'	'	'	'	'	'	'	($9,050)	($8,628)	($14,638)
Foreign	'	'	'	'	'	'	'	'	-55,493	-46,570	-39,473
Total Current	'	'	'	'	'	'	'	'	-64,543	-55,198	-54,111
Deferred:	'	'	'	'	'	'	'	'	'	'	'
Domestic (U.S.)	'	'	'	'	'	'	'	'	4,765	4,452	8,571
Foreign	'	'	'	'	'	'	'	'	10,756	8,028	9,796
Total Deferred	'	'	'	'	'	'	'	'	15,521	12,480	18,367
Provision for income taxes	-10,741	-12,876	-10,179	-15,226	-12,622	-9,180	-9,305	-11,611	-49,022	-42,718	-35,744
Components of Deferred Tax Assets and Liabilities [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Employee share-based compensation	16,764	'	'	'	16,288	'	'	'	16,764	16,288	'
Receivables	2,443	'	'	'	3,011	'	'	'	2,443	3,011	'
Inventory reserve	1,527	'	'	'	1,339	'	'	'	1,527	1,339	'
Property, plant and equipment	-13,718	'	'	'	-11,264	'	'	'	-13,718	-11,264	'
Intangible assets and goodwill	-122,079	'	'	'	-115,405	'	'	'	-122,079	-115,405	'
Debt issuance costs	-1,628	'	'	'	-2,044	'	'	'	-1,628	-2,044	'
Employee benefit accruals	7,997	'	'	'	7,072	'	'	'	7,997	7,072	'
Deferred income	2,234	'	'	'	-353	'	'	'	2,234	-353	'
Valuation allowances	-3,249	'	'	'	-876	'	'	'	-3,249	-876	'
Intercompany profit elimination	8,638	'	'	'	6,736	'	'	'	8,638	6,736	'
Other	2,603	'	'	'	1,521	'	'	'	2,603	1,521	'
Tax loss carryforward	10,812	'	'	'	8,386	'	'	'	10,812	8,386	'
Total deferred tax liabilities, net	($87,656)	'	'	'	($85,589)	'	'	'	($87,656)	($85,589)	'

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Income Tax Examination [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Effect of change in tax rate from prior year related to a non-cash remeasurment of deferred tax assets and liabilities	'	'	'	'	'	'	'	'	'	$2,236	'
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Income before income taxes	47,217	53,649	42,412	54,293	47,473	39,909	40,460	50,481	197,571	178,323	159,529
Computed tax provision	'	'	'	'	'	'	'	'	-69,782	-66,559	-55,801
Foreign tax differential	'	'	'	'	'	'	'	'	26,524	25,821	23,863
Non deductible expenses	'	'	'	'	'	'	'	'	-236	-1,298	-1,826
Permanent differences relating to German trade taxes	'	'	'	'	'	'	'	'	-1,421	-1,220	-1,143
Subpart F income net of tax credit	'	'	'	'	'	'	'	'	0	0	-113
Share-based compensation	'	'	'	'	'	'	'	'	667	-72	-3,007
Tax income (expense) from prior periods	'	'	'	'	'	'	'	'	157	-1,241	44
Tax free income and tax credits	'	'	'	'	'	'	'	'	645	2,174	1,684
Additional state taxes	'	'	'	'	'	'	'	'	-1,133	-511	-909
Change in tax rate	'	'	'	'	'	'	'	'	-2,236	0	0
Change in valuation allowance	'	'	'	'	'	'	'	'	-2,259	-91	1,493
Other	'	'	'	'	'	'	'	'	52	279	-29
Provision for income taxes	-10,741	-12,876	-10,179	-15,226	-12,622	-9,180	-9,305	-11,611	-49,022	-42,718	-35,744
Operating loss carryforwards, future expiration	'	'	'	'	'	'	'	'	'	'	'
2014	111	'	'	'	'	'	'	'	111	'	'
2015	1,048	'	'	'	'	'	'	'	1,048	'	'
2016	388	'	'	'	'	'	'	'	388	'	'
2017	1,379	'	'	'	'	'	'	'	1,379	'	'
2018	1,557	'	'	'	'	'	'	'	1,557	'	'
2019-2034	15,105	'	'	'	'	'	'	'	15,105	'	'
Subtotal	19,588	'	'	'	'	'	'	'	19,588	'	'
Indefinite	15,494	'	'	'	'	'	'	'	15,494	'	'
Total	35,082	'	'	'	'	'	'	'	35,082	'	'
Germany	'	'	'	'	'	'	'	'	'	'	'
Income Tax Examination [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Expense related to tax audit	'	'	'	'	'	'	'	'	'	$1,733	'

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	3 Months Ended								12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Components of income before taxes	'	'	'	'	'	'	'	'	'	'	'
Germany	'	'	'	'	'	'	'	'	$125,262,000	$112,963,000	$102,693,000
United States	'	'	'	'	'	'	'	'	23,230,000	16,590,000	16,236,000
Other Foreign	'	'	'	'	'	'	'	'	49,079,000	48,770,000	40,600,000
Income before taxes	47,217,000	53,649,000	42,412,000	54,293,000	47,473,000	39,909,000	40,460,000	50,481,000	197,571,000	178,323,000	159,529,000
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'	'	'	'	'	'	'	'	'
Undistributed foreign earnings	409,000,000	'	'	'	'	'	'	'	409,000,000	'	'
Valuation allowance of deferred tax assets	'	'	'	'	'	'	'	'	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'	'	'	'	'	'	'	'	'
Balance at Beginning of Period	'	'	'	876,000	'	'	'	1,031,000	876,000	1,031,000	2,208,000
Charged to Cost and Expense	'	'	'	'	'	'	'	'	'	0	0
Charged to Other Accounts	'	'	'	'	'	'	'	'	2,373,000	116,000	'
Deductions	'	'	'	'	'	'	'	'	0	271,000	1,177,000
Balance at End of Period	$3,249,000	'	'	'	$876,000	'	'	'	$3,249,000	$876,000	$1,031,000

Accrued_liabilities_and_deferr2

Accrued liabilities and deferred income (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
In Thousands, unless otherwise specified
Accrued Liabilites And Deferred Income [Abstract]	'	'	'
Employee benefits (e.g. bonuses, vacation, overtime, holiday payment)	$43,455	$34,678	'
Product warranty	9,694	8,482	8,735
Customer rebates and bonuses	35,323	13,752	'
Other provisions and liabilities	52,125	40,703	'
Deferred income	21,744	20,460	'
Total	$162,341	$118,075	'

Shortterm_debt_and_current_por2

Short-term debt and current portion of long-term debt (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
In Thousands, unless otherwise specified
Short Term Debt And Current Portion Of Long Term Debt [Abstract]	'	'
Accrued interest on long-term debt	$270	$270
Other short-term debt	177	208
Short-term debt and current portion of long-term debt	$447	$478

Longterm_debt_Details

Long-term debt (Details)

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Nov. 16, 2011

Mar. 31, 2010

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Nov. 16, 2011

Nov. 16, 2011

Nov. 16, 2011

USD ($)

USD ($)

New Senior Facilities Agreement

New Senior Facilities Agreement

Interest rate swap contracts

Interest rate swap contracts

Senior term loan, Tranche A2

Senior term loan, Tranche A2

Facilitya A Term Loan

Facilitya A Term Loan

Facilitya A Term Loan

Facilitya A Term Loan

Revolving Facility B

Revolving Facility C

USD ($)

Prior Senior Facilities Agreement

New Senior Facilities Agreement

USD ($)

USD ($)

New Senior Facilities Agreement

New Senior Facilities Agreement

New Senior Facilities Agreement

New Senior Facilities Agreement

USD ($)

EUR (€)

USD ($)

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, actual interest rate

'

'

'

'

'

'

2.88%

2.88%

'

'

'

'

'

'

Average annual interest rate for the variable rate senior term loans

2.88%

2.27%

'

'

'

'

'

'

'

'

'

'

'

'

Bank loans:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt including current maturities

$75,270,000

$75,270,000

'

'

'

'

'

'

$75,270,000

$75,270,000

'

'

'

'

Less current portion

270,000

270,000

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt

75,000,000

75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Senior Term Loans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

75,000,000

120,000,000

100,000,000

Debt Instrument, Payment Terms

'

'

'

'

'

'

'

'

'

'

'Of the amount borrowed under the Facility A Term Loan, 30% is due on November 16, 2015, and the balance is due on November 16, 2016.

'

'

'

Debt Instrument, Interest Rate Terms

'

'

'The loans under the New Senior Facilities Agreement bear interest of EURIBOR, for Euro-denominated loans, and LIBOR for the other loans, plus an initial margin of 160, 85 and 110 basis points for the Facility A Term Loan, Revolving Facility B and Revolving Facility C, respectively.

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Margin Ratchet Description

'

'

'The New Senior Facilities Agreement contains a margin ratchet. Pursuant to this provision, which will apply from March 31, 2012 onwards, the applicable margin will vary depending on the Company’s leverage multiple (i.e. the ratio of consolidated total net debt to consolidated adjusted EBITDA as defined in the new Senior Facilities Agreement) between 160 basis points and 215 basis points for the Facility A Term Loan, 85 basis points and 140 basis points for the Revolving Facility B, and 110 basis points and 165 basis points for the Revolving Facility C.

'

'

'

'

'

'

'

'

'

'

'

Deferred Finance Costs, Gross

'

'

'

$2,800,000

'

'

'

'

'

'

'

'

'

'

Derivative, Lower Fixed Interest Rate Range

'

'

'

'

3.50%

1.27%

'

'

'

'

'

'

'

'

Longterm_debt_Details_1

Long-term debt (Details 1) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Maturities of long term debt [Abstract]	'
2014	$447
2015	0
2016	22,500
2017	52,500
2018	0
Total debt outstanding	$75,447

Deferred_income_Details

Deferred income (Details) (USD $)	3 Months Ended								12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Deferred Revenue Arrangement [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Deferred Revenue, Revenue Recognized	'	'	'	'	'	'	'	'	($10,000,000)	($10,000,000)	($10,000,000)
(Gain)/loss on foreign currency transactions, net	1,848,000	4,510,000	1,417,000	4,580,000	-382,000	2,675,000	1,350,000	2,230,000	12,355,000	5,873,000	-5,668,000
Exclusivity Payment, Patterson	'	'	'	'	'	'	'	'	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Deferred Revenue	100,000,000	'	'	'	'	'	'	'	100,000,000	'	'
Deferred Revenue, Revenue Recognized	'	'	'	'	'	'	'	'	10,000,000	10,000,000	10,000,000
(Gain)/loss on foreign currency transactions, net	'	'	'	'	'	'	'	'	$1,900,000	($2,600,000)	($500,000)

Income_per_share_Details

Income per share (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Income Per Share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net income attributable to Sirona Dental Systems, Inc. shareholders	$36,235	$40,550	$31,658	$38,302	$34,736	$30,298	$30,521	$38,277	$146,745	$133,832	$121,793
Weighted average shares outstanding - basic	54,980,287	55,002,236	54,928,332	55,004,471	55,128,904	55,507,312	55,683,043	55,783,648	54,979,044	55,524,188	55,735,422
Dilutive effect of stock-based compensation	'	'	'	'	'	'	'	'	1,234,948	1,231,208	1,557,574
Weighted average shares - diluted	56,090,777	56,220,901	56,202,296	56,327,927	56,388,273	56,717,943	56,916,390	57,121,505	56,213,992	56,755,396	57,292,996
Net income per share	'	'	'	'	'	'	'	'	'	'	'
Basic	$0.66	$0.74	$0.58	$0.70	$0.63	$0.55	$0.55	$0.69	$2.67	$2.41	$2.19
Diluted	$0.65	$0.72	$0.56	$0.68	$0.62	$0.53	$0.54	$0.67	$2.61	$2.36	$2.13
Stock options excluded from computation of diluted earnings per share	'	'	'	'	'	'	'	'	0	0	0

Commitments_and_contingencies_1

Commitments and contingencies (Details)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2013
	USD ($)	EUR (€)	USD ($)	USD ($)	Inventories [Member]
					USD ($)
Operating lease commitments	'	'	'	'	'
Operating Leases, Rent Expense	$16,358	'	$14,888	$12,783	'
Sale Leaseback Transaction, Date	'July-05	'July-05	'	'	'
Sale Leaseback Transaction, Lease Terms	'Sirona leased the property from the property development company through an 18-year lease	'Sirona leased the property from the property development company through an 18-year lease	'	'	'
Sale Leaseback Transaction, Monthly Annual Payments	1,623	1,202	'	'	'
Operating Leases, Future Minimum Payments Due [Abstract]	'	'	'	'	'
2014	13,499	'	'	'	'
2015	11,370	'	'	'	'
2016	9,098	'	'	'	'
2017	7,428	'	'	'	'
2018	5,902	'	'	'	'
Thereafter	18,186	'	'	'	'
Total	65,483	'	'	'	'
Unrecorded Unconditional Purchase Obligation [Line Items]	'	'	'	'	'
Unconditional Purchase Commitments	'	'	'	'	$14,184
Unconditional Purchase Commitments Term	'	'	'	'	'due over a period of from one to three years

Product_warranty_Details

Product warranty (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Changes in the product warranty accrual	'	'
Balance at beginning of the period	$8,482	$8,735
Accruals for warranties issued during the period	19,118	17,726
Warranty settlements made during the period	-18,277	-17,651
Translation adjustment	371	-328
Balance at end of the period	$9,694	$8,482

Interest_Details

Interest (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Interest [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Interest expense	'	'	'	'	'	'	'	'	($3,975)	($4,603)	($5,763)
Interest income	'	'	'	'	'	'	'	'	565	836	1,880
Interest income (expense), net	($822)	($788)	($830)	($970)	($984)	($866)	($1,014)	($903)	($3,410)	($3,767)	($3,883)

Pension_plans_Details

Pension plans (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]	'	'	'
Projected benefit obligation at beginning of period	$74,712	$62,255	'
Service cost	1,426	1,069	'
Interest cost	2,127	2,483	2,510
Actuarial loss/(gain)	1,149	13,535	'
Investment earnings	222	409	'
Benefits paid	-2,568	-2,303	'
Currency translation	3,404	-2,736	'
Projected benefit obligation at end of period	80,472	74,712	62,255
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]	'	'	'
Fair value of plan assets at beginning of period	13,083	12,578	'
Actual return on plan assets	222	409	'
Employer's contribution	1,223	857	'
Benefits paid	-648	-218	'
Currency Translation	607	-543	'
Fair value of plan assets at end of period	14,487	13,083	12,578
Funded status	-65,985	-61,629	'
Components of net periodic costs	'	'	'
Service cost, net	203	212	578
Interest cost	2,127	2,483	2,510
Amortization of actuarial gains	128	-310	-164
Net periodic benefit cost	2,458	2,385	2,924
Defined Benefit Plan, Accumulated Benefit Obligation	$64,978	$60,614	'
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	3.56%	4.16%	'

Pension_plans_Details_1

Pension plans (Details 1) (USD $)	12 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
				U.S. Plan	U.S. Plan	Foreign Plan	Foreign Plan
Defined Benefit Plan, Estimated Future Benefit Payments [Abstract]	'	'	'	'	'	'	'
2014	$3,835	'	'	'	'	'	'
2015	2,886	'	'	'	'	'	'
2016	3,131	'	'	'	'	'	'
2017	2,887	'	'	'	'	'	'
2018	3,231	'	'	'	'	'	'
5 Years thereafter	17,092	'	'	'	'	'	'
Total	33,062	'	'	'	'	'	'
Defined Benefit Plan Expected Contributionss [Abstract]	'	'	'	'	'	'	'
2014	1,277	'	'	'	'	'	'
2015	1,281	'	'	'	'	'	'
2016	1,260	'	'	'	'	'	'
2017	1,240	'	'	'	'	'	'
2018	1,221	'	'	'	'	'	'
5 Years thereafter	11,835	'	'	'	'	'	'
Total	18,114	'	'	'	'	'	'
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]	'	'	'	'	'	'	'
Discount rate	3.40%	3.50%	5.25%	'	'	'	'
Defined Contribution Pension And Other Postretirement Plans Disclosure [Line Items]	'	'	'	'	'	'	'
Contributions made to the plan	'	'	'	$801	$688	$931	$747
U.S. 401(K) Plan	'The Company is obligated to match employee contributions as defined in the plans	'	'	'	'	'	'

Net_Other_Operating_Income_and2

Net Other Operating Income and Restructuring Costs (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	'	'	'	'	'	'	'	'	$10,000	$10,000	$10,000
Gain/(Loss) from patent infringement settlement	'	'	'	'	'	'	'	'	4,414	0	0
Net other operating income	$2,500	$2,500	$2,500	$6,914	$2,500	$2,500	$2,500	$2,500	$14,414	$10,000	$10,000

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Strategies (Details) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Mar. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Mar. 31, 2012

Mar. 31, 2010

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Prior Senior Facilities Agreement

Loss/(Gain) on derivative instruments

Loss/(Gain) on derivative instruments

Loss/(Gain) on derivative instruments

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Prior Senior Facilities Agreement

Prior Senior Facilities Agreement

New Senior Facilities Agreement

Loss/(Gain) on derivative instruments

Loss/(Gain) on derivative instruments

Loss/(Gain) on derivative instruments

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Loss/(Gain) on derivative instruments

Loss/(Gain) on derivative instruments

Loss/(Gain) on derivative instruments

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Not Designated as Hedging Instrument

Interest Rate Risk

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of Debt Hedged by Interest Rate Derivatives

'

'

'

'

'

'

'

'

'

'

'

66.60%

'

'

'

66.70%

'

100.00%

'

'

'

'

'

'

'

'

Derivative, Lower Fixed Interest Rate Range

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.50%

1.27%

'

'

'

'

'

'

'

'

Derivative, Higher Fixed Interest Rate Range

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.24%

1.29%

'

'

'

'

'

'

'

'

Foreign Currency Exposure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$38,100,000

$34,300,000

'

'

'

Loss/(gain) on derivative instruments

-738,000

-901,000

2,564,000

-1,346,000

-2,147,000

2,686,000

-2,936,000

436,000

-421,000

-1,961,000

3,302,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impact of gains and losses from the fair value changes of the derivative instruments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

(Gain)/Loss Recognized in Accumulated Other Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-970,000

2,096,000

0

'

'

'

'

'

Ineffective portion Recognized in Income

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

2,000

0

'

'

'

'

'

(Gain)/Loss Recognized in Income

'

'

'

'

'

'

'

'

'

'

'

'

($421,000)

($1,963,000)

$3,302,000

'

'

'

'

'

'

'

'

($421,000)

($1,963,000)

$3,302,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
In Thousands, unless otherwise specified
Liabilities	'	'
Business Acquisition-related liabilities	($13,400)	'
Fair Value, Measurements, Recurring	'	'
Assets	'	'
Cash Equivalents (money market funds)	31,317	84,216
Derivative Assets	917	730
Liabilities	'	'
Derivative Liabilities	-59	-356
Business Acquisition-related liabilities	-13,407	-7,864
Total	18,768	76,726
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Instruments (Level 1)	'	'
Assets	'	'
Cash Equivalents (money market funds)	31,317	84,216
Derivative Assets	'	0
Liabilities	'	'
Derivative Liabilities	'	0
Business Acquisition-related liabilities	'	0
Total	31,317	84,216
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Foreign exchange contracts	'	'
Assets	'	'
Derivative Assets	917	730
Liabilities	'	'
Derivative Liabilities	-59	-356
Business Acquisition-related liabilities	'	0
Total	858	374
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)	'	'
Assets	'	'
Derivative Assets	'	0
Liabilities	'	'
Derivative Liabilities	'	0
Business Acquisition-related liabilities	-13,407	-7,864
Total	($13,407)	($7,864)

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	12 Months Ended
	Sep. 30, 2013
Business Fair Value Measurement [Line Items]	'
Business Combination Contingent Consideration Liability	$13,400,000
Changes in fair value of contingent consideration	-100,000
Technology Company	'
Business Fair Value Measurement [Line Items]	'
Business Combination Contingent Consideration Liability	$5,600,000

Segment_reporting_Details

Segment reporting (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	$278,604	$283,157	$267,326	$272,404	$247,364	$242,007	$231,864	$258,116	$1,101,491	$979,351	$913,866
Segment Performance Measure	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	629,116	567,750	534,122
Depreciation and amortization expense	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	34,993	29,800	26,232
Total Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	1,114,319	1,013,661	950,038
Total segments	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	1,101,491	977,682	912,671
Segment Performance Measure	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	623,160	559,946	524,286
Depreciation and amortization expense	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	32,454	27,789	24,981
Total segments | Total Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	1,114,319	989,540	923,927
Dental CAD/CAM Systems	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	409,328	334,539	306,743
Segment Performance Measure	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	276,672	233,829	214,133
Depreciation and amortization expense	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	13,533	10,260	8,131
Dental CAD/CAM Systems | Total Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	409,328	334,539	306,743
Imaging Systems	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	378,042	343,528	319,774
Segment Performance Measure	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	221,907	199,526	187,375
Depreciation and amortization expense	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	6,576	6,010	6,191
Imaging Systems | Internal Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	0	20	17
Imaging Systems | Total Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	378,042	343,548	319,791
Treatment Centers	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	210,666	197,144	183,879
Segment Performance Measure	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	81,369	79,625	73,179
Depreciation and amortization expense	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	7,379	7,596	7,180
Treatment Centers | Internal Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	6	6	21
Treatment Centers | Total Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	210,672	197,150	183,900
Instruments	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	103,455	102,471	102,275
Segment Performance Measure	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	43,212	46,966	49,599
Depreciation and amortization expense	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	4,966	3,923	3,479
Instruments | Internal Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	12,822	11,832	11,218
Instruments | Total Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	116,277	114,303	113,493
Intercompany elimination, reportable segments | Internal Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	-12,828	-11,858	-11,256
Electronic center and corporate	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	0	1,669	1,195
Segment Performance Measure	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	5,956	7,804	9,836
Depreciation and amortization expense	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	2,539	2,011	1,251
Electronic center and corporate | Internal Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	0	22,452	24,917
Electronic center and corporate | Total Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	0	24,121	26,111
Intercompany elimination | Internal Revenue Per Segment	'	'	'	'	'	'	'	'	'	'	'
Revenue Total	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	$0	($22,452)	($24,917)

Segment_reporting_Details_1

Segment reporting (Details 1) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Revenue	'	'	'	'	'	'	'	'	'	'	'
Consolidated revenue	$278,604	$283,157	$267,326	$272,404	$247,364	$242,007	$231,864	$258,116	$1,101,491	$979,351	$913,866
Depreciation and amortization	'	'	'	'	'	'	'	'	'	'	'
Consolidated depreciation and amortization	'	'	'	'	'	'	'	'	75,595	77,749	81,173
Segement performance measure	'	'	'	'	'	'	'	'	'	'	'
Consolidated gross profit	143,291	151,487	144,706	151,871	132,079	128,440	124,649	138,783	591,355	523,951	483,652
Selling, general and administrative expense	83,372	79,702	83,992	85,783	76,912	72,434	72,667	73,646	332,849	295,659	277,081
Research and development	14,649	15,729	15,102	14,095	12,606	13,092	13,638	13,286	59,575	52,622	55,530
Provision for doubtful accounts and notes receivable	-152	148	547	70	-338	-504	728	39	613	-75	96
Net other operating income	-2,500	-2,500	-2,500	-6,914	-2,500	-2,500	-2,500	-2,500	-14,414	-10,000	-10,000
(Gain)/loss on foreign currency transactions, net	1,848	4,510	1,417	4,580	-382	2,675	1,350	2,230	12,355	5,873	-5,668
(Gain)/loss on derivative instruments	-738	-901	2,564	-1,346	-2,147	2,686	-2,936	436	-421	-1,961	3,302
Interest expense, net	822	788	830	970	984	866	1,014	903	3,410	3,767	3,883
Other (income)/expense	-1,227	362	342	340	-529	-218	228	262	-183	-257	-101
Income before taxes	47,217	53,649	42,412	54,293	47,473	39,909	40,460	50,481	197,571	178,323	159,529
Total segments	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	'	'	'
Consolidated revenue	'	'	'	'	'	'	'	'	1,101,491	977,682	912,671
Depreciation and amortization	'	'	'	'	'	'	'	'	'	'	'
Consolidated depreciation and amortization	'	'	'	'	'	'	'	'	32,454	27,789	24,981
Segement performance measure	'	'	'	'	'	'	'	'	'	'	'
Consolidated gross profit	'	'	'	'	'	'	'	'	623,160	559,946	524,286
Dental CAD/CAM Systems	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	'	'	'
Consolidated revenue	'	'	'	'	'	'	'	'	409,328	334,539	306,743
Imaging Systems	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	'	'	'
Consolidated revenue	'	'	'	'	'	'	'	'	378,042	343,528	319,774
Treatment Centers	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	'	'	'
Consolidated revenue	'	'	'	'	'	'	'	'	210,666	197,144	183,879
Instruments	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	'	'	'
Consolidated revenue	'	'	'	'	'	'	'	'	103,455	102,471	102,275
Electronic center and corporate	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	'	'	'
Consolidated revenue	'	'	'	'	'	'	'	'	0	1,669	1,195
Differences management reporting vs. US GAAP, electronic center and corporate	'	'	'	'	'	'	'	'	'	'	'
Depreciation and amortization	'	'	'	'	'	'	'	'	'	'	'
Consolidated depreciation and amortization	'	'	'	'	'	'	'	'	43,141	49,960	56,192
Segement performance measure	'	'	'	'	'	'	'	'	'	'	'
Consolidated gross profit	'	'	'	'	'	'	'	'	($31,805)	($35,995)	($40,634)

Segment_reporting_Details_2

Segment reporting (Details 2) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Total assets	'	'	'	'	'	'	'	'	'	'	'
Total	$1,738,419	'	'	'	$1,494,534	'	'	'	$1,738,419	$1,494,534	'
Goodwill	'	'	'	'	'	'	'	'	'	'	'
Total	672,086	'	'	'	631,077	'	'	'	672,086	631,077	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	278,604	283,157	267,326	272,404	247,364	242,007	231,864	258,116	1,101,491	979,351	913,866
Long-lived assets	188,357	'	'	'	152,733	'	'	'	188,357	152,733	'
Germany	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	198,630	159,327	189,005
Long-lived assets	159,766	'	'	'	130,314	'	'	'	159,766	130,314	'
United States	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	336,689	284,932	255,874
Long-lived assets	6,459	'	'	'	5,434	'	'	'	6,459	5,434	'
Rest of World	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	566,172	535,092	468,987
Long-lived assets	22,132	'	'	'	16,985	'	'	'	22,132	16,985	'
Total segments	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	1,101,491	977,682	912,671
Dental CAD/CAM Systems	'	'	'	'	'	'	'	'	'	'	'
Total assets	'	'	'	'	'	'	'	'	'	'	'
Total	834,441	'	'	'	657,595	'	'	'	834,441	657,595	'
Goodwill	'	'	'	'	'	'	'	'	'	'	'
Total	315,880	'	'	'	296,605	'	'	'	315,880	296,605	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	409,328	334,539	306,743
Imaging Systems	'	'	'	'	'	'	'	'	'	'	'
Total assets	'	'	'	'	'	'	'	'	'	'	'
Total	469,373	'	'	'	448,360	'	'	'	469,373	448,360	'
Goodwill	'	'	'	'	'	'	'	'	'	'	'
Total	201,626	'	'	'	176,702	'	'	'	201,626	176,702	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	378,042	343,528	319,774
Treatment Centers	'	'	'	'	'	'	'	'	'	'	'
Total assets	'	'	'	'	'	'	'	'	'	'	'
Total	278,147	'	'	'	254,071	'	'	'	278,147	254,071	'
Goodwill	'	'	'	'	'	'	'	'	'	'	'
Total	94,092	'	'	'	94,662	'	'	'	94,092	94,662	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	210,666	197,144	183,879
Instruments	'	'	'	'	'	'	'	'	'	'	'
Total assets	'	'	'	'	'	'	'	'	'	'	'
Total	156,458	'	'	'	134,508	'	'	'	156,458	134,508	'
Goodwill	'	'	'	'	'	'	'	'	'	'	'
Total	60,488	'	'	'	63,108	'	'	'	60,488	63,108	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	$103,455	$102,471	$102,275

Segment_reporting_Details_3

Segment reporting (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Concentration Risk [Line Items]	'	'	'
Accounts Receivable Net Current	145,212	132,569	'
Sales Revenue, Goods, Net [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk, Percentage	47.00%	44.00%	44.00%
Sales Revenue, Goods, Net [Member] | Patterson Dental Company, Inc.	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk, Percentage	33.00%	29.00%	27.00%
Sales Revenue, Goods, Net [Member] | Henry Schein, Inc.	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk, Percentage	14.00%	15.00%	17.00%
Accounts Receivable [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Accounts Receivable Net Current	73,468	55,015	26,848

Related_parties_Details

Related parties (Details) (USD $)	12 Months Ended			1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	31-May-11	Mar. 31, 2011
				Luxco	Luxco
Related Party Transaction [Line Items]	'	'	'	'	'
Shares sold pursuant to an underwritten follow-on public offering	'	'	'	9,747,480	4,500,000
Sale of stock, costs incurred	'	'	'	$200,000	$300,000
One-time non-cash compensation charge (payment by shareholder - Note 24)	$0	$0	$6,625,000	'	'

Unaudited_quarterly_informatio2

Unaudited quarterly information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Unaudited Quarterly Information [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenue	$278,604	$283,157	$267,326	$272,404	$247,364	$242,007	$231,864	$258,116	$1,101,491	$979,351	$913,866
Cost of sales	135,313	131,670	122,620	120,533	115,285	113,567	107,215	119,333	510,136	455,400	430,214
Gross profit	143,291	151,487	144,706	151,871	132,079	128,440	124,649	138,783	591,355	523,951	483,652
Operating expenses/(income):	'	'	'	'	'	'	'	'	'	'	'
Selling, general and administrative expense	83,372	79,702	83,992	85,783	76,912	72,434	72,667	73,646	332,849	295,659	277,081
Research and development	14,649	15,729	15,102	14,095	12,606	13,092	13,638	13,286	59,575	52,622	55,530
Provision for doubtful accounts and notes receivable	-152	148	547	70	-338	-504	728	39	613	-75	96
Net other operating income	-2,500	-2,500	-2,500	-6,914	-2,500	-2,500	-2,500	-2,500	-14,414	-10,000	-10,000
Operating income	47,922	58,408	47,565	58,837	45,399	45,918	40,116	54,312	212,732	185,745	160,945
(Gain)/loss on foreign currency transactions, net	1,848	4,510	1,417	4,580	-382	2,675	1,350	2,230	12,355	5,873	-5,668
(Gain)/loss on derivative instruments	-738	-901	2,564	-1,346	-2,147	2,686	-2,936	436	-421	-1,961	3,302
Interest expense, net	822	788	830	970	984	866	1,014	903	3,410	3,767	3,883
Other (income)/expense	-1,227	362	342	340	-529	-218	228	262	-183	-257	-101
Income before taxes	47,217	53,649	42,412	54,293	47,473	39,909	40,460	50,481	197,571	178,323	159,529
Income tax provision	10,741	12,876	10,179	15,226	12,622	9,180	9,305	11,611	49,022	42,718	35,744
Net income	36,476	40,773	32,233	39,067	34,851	30,729	31,155	38,870	148,549	135,605	123,785
Less: Net income attributable to noncontrolling interests	241	223	575	765	115	431	634	593	1,804	1,773	1,992
Net income attributable to Sirona Dental Systems, Inc. shareholders	$36,235	$40,550	$31,658	$38,302	$34,736	$30,298	$30,521	$38,277	$146,745	$133,832	$121,793
Income per share (attributable to Sirona Dental Systems, Inc. common shareholders)	'	'	'	'	'	'	'	'	'	'	'
Net income per share - basic	$0.66	$0.74	$0.58	$0.70	$0.63	$0.55	$0.55	$0.69	$2.67	$2.41	$2.19
Net income per share - diluted	$0.65	$0.72	$0.56	$0.68	$0.62	$0.53	$0.54	$0.67	$2.61	$2.36	$2.13
Weighted average shares - basic	54,980,287	55,002,236	54,928,332	55,004,471	55,128,904	55,507,312	55,683,043	55,783,648	54,979,044	55,524,188	55,735,422
Weighted average shares - diluted	56,090,777	56,220,901	56,202,296	56,327,927	56,388,273	56,717,943	56,916,390	57,121,505	56,213,992	56,755,396	57,292,996